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Abstract 
Flaviviruses compose a group of positive single strand RNA viruses. This group 
possess 70 individual viruses that cause disease in humans and animals. This group 
contains the most prevalent arbovirus dengue virus (DENV) and a recently emerging 
arbovirus zika virus (ZIKV). Both DENV and ZIKV represent significant world health 
threats and both viruses, at the moment, are contained to tropical and sub tropical 
regions due to vector habitat restrictions. DENV can cause severe hemorrhagic fever 
termed dengue hemorrhagic fever and dengue shock syndrome depending on the 
extent of vascular permeability. The disease burden attributed to dengue infection is 
approximately 390 million infections per year. Of these infections, 96 million will result in 
clinical disease and 500,000 patients require hospitalization resulting in 25,000 deaths a 
year. ZIKV presents a less severe disease pathology, with a majority of infections in 
healthy adults being asymptomatic. The more severe infections in adults result in an 
autoimmune disease called Guillain-Barre syndrome. What caused the world health 
organization to declare ZIKV a world health emergency in 2016 is the viruses’ ability to 
transverse the placenta barrier and infect a developing fetus. The most severe symptom 
associated with in utero infection is the development of microcephaly, which leads to 
severe cognitive impairment. As case studies expand and the disease pathology of 
ZIKV is more fully understood a class of symptoms termed congenital zika syndrome 
fully classifies the extent of cognitive abnormalities induced by this virus.  A 
commonality of these two viruses is that there are no approved treatments for either of 
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these viral infections. A vaccine for DENV was recently introduced, but due to 
immunological complications it was withdrawn from distribution. A significant issue to 
combat with the development of therapies for dengue and zika viral infection is the 
induction of antibody dependent enhancement (ADE). ADE is mediated when cross-
reactive low affinity antibodies bind to the virus and are internalized via the FcγR on 
myeloid cells, but do not neutralize the virus resulting in an induction of pro-
inflammatory cytokines and increased viral titer. In the studies presented here we 
hypothesized that the utilization of avian IgY, which does not interact with mammalian 
Fc receptors, would provide a viable therapy for ZIKV and DENV viral infection. 
Polyvalent anti-ZIKV IgY was purified from eggs of ZIKV immunized geese. The purified 
anti-ZIKV IgY preparation was assessed for it’s ability to neutralize ZIKV infection in 
vitro and in vivo. We also assessed for the ability of polyvalent anti-ZIKV IgY to enhance 
viral infection in vitro. Our data suggests that anti-ZIKV IgY is able to neutralize ZIKV 
infection in vitro and in vivo without inducing ADE. Our data also demonstrates novel 
viral epitopes recognized in our polyvalent anti-ZIKV IgY preparation. Previously our lab 
had established that polyvalent anti-DENV IgY was able to neutralize ZIKV infection in 
vitro and in vivo without inducing ADE. Novel non-structural protein 1 (NS1) epitopes 
were recognized and determined by microarray analysis. In our study we expand upon 
this work and determine if the novel NS1 IgY have the ability to neutralize DENV 
infection in vitro and in vivo. Our data suggests that anti-NS1 IgY has the ability to 
neutralize DENV infection in vitro and in vivo. This is highly atypically of anti-NS1 DENV 
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antibodies, which typically only exhibit efficacy in vivo. Thus our data suggests not only 
a novel epitope of neutralization, but a unique neutralization mechanism distinctive to 
IgY. Due to the emergence of zika virus as a global health threat a greater vector 
competency profile was needed to be conducted to estimate the true pathogenic range 
and which populations could be potentially at risk. In collaboration with the Biology 
department at UND we conducted vector competency studies of mosquito species 
native to the region. To our surprise our common pest mosquito Aedes vexans was not 
only able to establish a midgut infection, but also developed disseminated infection in a 
small percentage of cases. We then tested the ability for the mosquito to transmit the 
virus under laboratory settings and Aedes vexans were able to transmit the virus at a 
much higher rate than the positive control population Aedes aegypti. This study greatly 
expands the potential geographical area that zika virus could potentially spread to, as 
Aedes vexans is common in many temperate climates across North America and 
Europe.  
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Chapter I 
Introduction Flaviviruses 
Flaviviruses compose a group of positive single strand RNA viruses. This group 
possesses 70 individual viruses that cause disease in humans and animals. All viruses 
in this group are named for the location in which they were discovered. This is divergent 
from many other viral groups which rely on genetic characteristics for nomenclature. 
Many of these pathogenic flaviviruses are arboviruses which indicates they are spread 
by mosquitoes or ticks. Of the 70 viruses that cause diseases 5 of them are of great 
public health concern for humans they are; Dengue virus, West Nile virus, Japanese 
encephalitis virus, Yellow fever virus, and Zika virus. Flaviviruses encode 10 genes 
three structural genes and seven non-structural genes. The structural genes are the 
lipid envelope (E) the pre-membrane (prM) and the internal capsid (C). These proteins 
are involved in composing the extra-RNA protective matrix, receptor fusion of an 
infectious virion, and immune evasion. The seven non-structural proteins are non-
structural protein 1 (NS1), non-structural protein 2a/b (NS2a, NS2b), non-structural 
protein 3 (NS3), non-structural protein 4a/b (NS4a, NS4b), and non-structural protein 5 
(NS5). The primary function of these proteins in developing the viral replication complex 
and copying the viral RNA for the production of mature virions. Many non-structural 
proteins also possess immune evasive properties particularly against intracellular innate 
pattern recognition receptors. Initially the viral RNA encodes a polyprotein precursor 
which is then enzymatically cleaved to individual viral proteins.  
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In further detail a model virion to describe viral replication of this group is DENV. The 50 
nm viral particle attaches to an extracellular receptor on susceptible host cells. The 
primary host receptor has not been fully elucidated, but many receptors have been 
demonstrated experimentally. The primary candidate is DC-SIGN/L-SIGN expressed on 
dendritic cells and macrophages (1, 2, 3). Heparan sulfate receptor is also a prime 
candidate as it has been identified as a receptor in multiple in vitro models of dengue 
virus infection including Vero cells, BHK-21 cells, and SW-13 cells (4, 5). Mannose 
receptor may be a target for viral attachment on macrophages (6). These three 
receptors are the only receptors identified that are involved in the internalization of all 
four DENV serotypes. The virion is then internalized by clathrin mediated endocytosis 
once the endosomal pH starts to lower a conformational change of the viral envelope 
exposes the DIII fusion loop that allow for the viral envelop to fuse with the endosomal 
membrane and release the viral ribonucleocpasid into the cytoplasm (7). Viral non-
structural proteins and host factors co-integrate and form a membrane associated 
replication complex that allows for viral RNA replication to take place. The viral 
replication complex is formed inside a vesicular compartment of the endoplasmic 
reticulum (ER) lumen. NS4A and B anchor the complex on the cytoplasmic side and a 
NS1 dimer anchors the ER lumen side. Protein-protein interactions between NS1 and 
NS4A and B has been demonstrated (8). NS4B is also in direct contact with NS3 which 
functions as the RNA helicase (9). This interaction is not complete without NS2B which 
is a co-factor for NS3 helicase activity (10). NS5 is the RNA dependent RNA 
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polymerase and methyltranserase which is important for RNA capping of the new viral 
genome. NS2A anchors the viral RNA to the ER lumen to allow for complete replication 
(11). The newly synthesized RNA is packaged by the capsid protein to start the 
formation of a new immature viral particle. The prM and E proteins form heterodimers in 
the ER lumen. Once integrated together into trimers a curved lattice structure is formed 
which directs virion budding (12, 13). The immature virion then travels through the 
trans-Golgi network. The moderately acidic pH of the trans-Golgi network induces a 
conformational change of the prM/E trimers to lie flat on the surface of the particle. This 
restructuring is critical to allow for the cellular endoprotease furin to cleave prM to 
generate the mature M and dissociate the “pr” particle that is then secreted from 
infected cells and act to evade host immune responses (14, 15, 16). The now mature 
virion is exocytosed from the cell preferentially through lipid rafts harboring NS1 dimers. 
As stated previously not only is the mature virion secreted but also pr and NS1 hexamer 
which as involved in immune evasion and increase in disease pathology.  
 
Flaviviral pathogenesis can be separated into two separate clades based on the 
type of clinical manifestations presented in patients. The first is clade are the viruses 
that induce hemorrhaging for the purpose of this dissertation Dengue virus will be used 
as an example as it is applicable to future studies in combating the pathogenesis. The 
second clade are those that induce neurological symptoms, Zika virus will be used as 
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an example in this dissertation even though it possesses unique characteristics and is 
not a stereotypical example of this clade.  
Infection with any of the four serotypes of DENV in a majority of cases result in 
an asymptomatic infection. Infections may progress into a wide variety of clinical 
manifestations ranging from mild flu like symptoms to more severe symptoms including 
vascular permeability and shock. The World Health Organization has four grades of 
dengue hemorrhagic fever (DHF). Grades I and II are less severe and do not induce 
shock. Grades III and IV cases are more severe and contain hypovolemic shock as a 
symptom. Pathology of DENV can be broken down into three major organs that play a 
role: immune system, the liver, and endothelial cell linings of blood vessels. Initial 
introduction of DENV to the host via the mosquito proboscis into the skin, which allows 
for the infection of Langerhans cells (17). These residential dendritic cells then migrate 
to local lymph nodes which exposes infiltrating monocytes and macrophages for 
infection. Once these cells have become infected the virus is then able to spread 
throughout the limbic system continually encountering susceptible cells for continued 
viral infection and replication (18-20). Secondary infection with a heterotypic serotype of 
DENV can result in antibody mediated infection of monocytes, but this will be explained 
in greater detail in the section on antibody dependent enhancement (ADE). 
Mononuclear cells primary die via apoptosis which in turns stimulates inflammatory 
mediators which contributes to the disease pathology (20, 21, 22). Organ pathology 
traditionally has been a challenge due to the lack of resources in endemic areas of this 
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disease and cultural traditions that inhibit autopsies from being performed. Virus has 
been identified in patients who died within 36 hour of developing shock in the skin, liver, 
spleen, lymph nodes, kidney, bone marrow, lung, thymus, and brain (23). Infectious 
virions could only be cultured from the liver and peripheral blood mononuclear cells 
(PBMCs), which could indicate that the virus in the other organs was degraded or in an 
immature state. Liver is typically associated with DENV infection in humans and mice. A 
unique attribute of this area of pathology is that little inflammation has been detected in 
the liver and the tissue disruption is directly viral related as compared to a secondary 
immune scaring event. Extensive work form the Eva Harris lab has demonstrated the 
pathogenic role of NS1 on the endothelial glycocalyx. This occurs when circulating 
pentameric NS1 molecules bind to the surface of endothelial cells in capillary beds. The 
interaction between the endothelial cell surface and NS1 results in the up regulation of 
sialadases Neu1-3, which leads to the cleavage of sialic acid on the surface of the 
endothelial cells. The binding of NS1 also induces an increased expression of cathepsin 
L, which in turns over expresses heperanase and results in the cleavage of hepran 
sulfate and hepran sulfate proteoglycans. When all of these processes occur 
simultaneously they result in loss of endothelial glycocalyx layer and barrier integrity 
(24).  
 Taking a closer look at the immune response elicited by DENV not all are 
favorable to the host. Four immunological events can contribute to DENV pathology: 
complement activation, ADE, cross reactive T-cells, and soluble factors. The 
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complement system is an integral part of the humoral innate response and can act 
rapidly when induced by a pathogen antigen. It has been previously demonstrated that 
high levels of complement activation subunits C3a and C5a are found circulating in 
patient blood whom develop DHF and dengue shock syndrome (DSS) (25, 26). NS1 
can induce antibodies that can target the dimeric NS1 expressed on infected cells. In 
other cases, these antibodies can target cells that NS1 is binding to inducing antibody 
mediated complement lyses of uninfected cells as well. (27). The generation of less 
than ideal antibodies in DENV infection is a common theme throughout the infection 
process. DENV utilizes a number of factors to evade or miss lead the antibody response 
to make it as ineffective as possible, such mechanism have previously been described 
as in NS1 over activating the complement system, pr is a potent B cell antigen that has 
no neutralization properties to a mature virion effectively DENV uses it as an antigenic 
decoy. One of the critical follies in the antibody repertoire of DENV infection is the 
production of high affinity and sub neutralizing antibodies. These antibodies have high 
affinity to the primary serotype the patient is infected with but on a secondary 
heterotypic infection they will bind, but not neutralize the virus enabling the virus to 
utilize FcγR’s as an additional route of infecting cells. This mechanism will be discussed 
later in a separate section. T cells like antibodies can be a double edge sword in DENV 
pathogenesis. Memory cross reactive CD8 T cells can provide robust protection (28), 
but they can also contribute to pathogenesis leading to the “original antigenic sin 
hypothesis.” The basis for this hypothesis is that low-avidity cross reactive CD8 T cells 
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would preferentially expand compared to high-avidity cross reactive CD8 T cells. The 
high-avidity cross reactive CD8 T cells produce robust pro- and anti-inflammatory 
cytokine response resulting in a balanced immune response that has the ability to lyse 
virally infected cells and then mitigate the immunological scaring due to the lysis 
process. Due to the robust activation of these cells they rapidly undergo apoptosis. This 
leaves a window for the low avidity CD8 T cells to preferentially expand in the place of 
the now expired high avidity counter parts. The low avidity CD8 T cells have the ability 
to produce high levels of pro-inflammatory cytokines, but lack effective cytolytic activity 
and produce minimal levels of anti-inflammatory cytokines to reduce immunological 
scaring (29, 30). This has lead to the development of a cytokine storm in severe dengue 
patients. Through multiple patient screenings a panel of cytokines has been complied 
that are consistently higher in plasma levels with patients with severe dengue disease 
these are; IL-1β, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-13, IL-18, TGF-1β, TNFα and IFNγ 
(31,32,33,34,35,36,37,38,39,40,41). The issue for researchers is to determine which 
cytokine or combination of cytokines are actually inducing the pathology and which are 
still protective. One of the key hallmarks of severe dengue disease is vascular 
permeability which can partially be attributed to the over production of TNFα and IL-6 
(42).The original antigenic sin hypothesis has also been observed in LCMV, Influenza, 
and MCMV (43, 44, 29). It is likely that not only factor contributes wholly to DENV 
pathogenesis. Some factors such as host genetic background are still being researched 
and are not fully understood how anomalies interact with the pathogenesis of the virus. 
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By placing the subsequent sections together an integrated mechanism of pathogenesis 
can be composed.  
 Pathogenesis of Zika virus early in infection is extremely similar to Dengue virus. 
During a mosquito blood meal, the virus is able to invade the body and infect 
keratinocytes, fibroblasts, and Langerhans cells (45,46,47). Once initially viral 
replication is successful viremia ensues and allows the virus to infect monocytes, which 
allows for the virus to spread throughout the body (48). Utilizing a “Trojan horse” 
methodology the infected monocytes are able to infiltrate immune privileged sites such 
as the brain, testes, and placenta (49). Presently, there is no physiologically established 
receptor for Zika viral infection. An attractive target that has shown promising results in 
vitro is the AXL receptor. This receptor is a member of the TAM family which interacts 
with Gas6 and Protein S which bind to the viral envelope (50). This receptor is 
expressed on the early cells in which the virus infects such as keratinocytes and 
endothelial cells (51, 52, 53). Even more promising is that AXL is also expressed on 
neural progenitor cells and target cells within the testes (54, 55). These two tissue 
tropism causes unique clinical manifestations. The first is the ability for the virus to infect 
neural progenitor cells, once the virus is within the neuron viral replication ensues and 
eventually induces apoptosis of the neuron. Continued viral replication results in major 
tissue damage resulting in major neuronal developmental abnormalities. Describing the 
clinical features of these outcomes is much more extensive. A large percentage (80%) 
of Zika infections are asymptomatic. The mild form of the disease with clinical 
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manifestations presents as a self-limiting febrile illness that lasts from 4-7 days. The 
more severe form of Zika infection results primarily when the virus is transmitted in 
utero. Microcephaly and Gullian-Barre syndrome rates were determined by Meta 
analysis of 2.3% and 1.23% of all pregnancies respectively (56,57). Many more 
neurological manifestations have been reported in Zika viral infections, these include 
craniofacial disproportion, spasticity, seizures, brainstem dysfunction, and feeding 
difficulties. More commonly than Microcephaly ocular abnormalities occur as a result of 
Zika viral infection, these include focal pigment mottling, chorioretinal macular atrophy, 
optic nerve abnormalities, cataract, intra-ocular calcifications, optic disk cupping, foveal 
reflex loss, macular hypoplasia, and scarring (58). To combat Zika viral infection a 
patients’ body first will induce an innate response. The early innate response is 
centralized around pattern recognition receptors recognizing viral pathogen associated 
molecular patterns. Most important of the early innate response is the stimulation of 
type I and type III interferons. Type-I interferons will induce the JAK/STAT pathway 
which allows for IRF9 to translocate to the nucleus and induce the expression of 
interferon stimulated genes. Type-III interferons are critical to combating the virus at the 
maternal fetal interface. The Adaptive immune response to Zika virus is very similar to 
Dengue viral infection and poses the same immunological issues.  
 A critical event in both Dengue and Zika viral infection is the induction of antibody 
dependent enhancement (ADE). The first description of ADE was by Halstead et al. 
describing Murray Valley encephalitis virus where higher concentrations of antibody 
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neutralized the virus on chicken embryo monolayer, but at lower concentrations the viral 
titer increased to levels much greater than the viral control. Initially the type of Fc 
receptor to which the antibody binds influences the effectiveness of the phagocytosis. 
FcγRIIA is more highly expressed and has been most associated with ADE (59). Once 
the antibody and receptor complex is formed a signaling cascade of ITAM molecules 
are phosphorylated which recruit Syk/ZAP-70 to initiate phagocytosis (60). The amount 
of antibody bound to the complex directly influences the amount of virus and the method 
in which the complex is internalized. A smaller amount of antibody will utilize clathrin 
mediated endocytosis to bring in a single viral particle. Larger amounts of antibodies will 
induce aggregates and phagocytize via the mechanism previously stated bringing in a 
larger amount of virus at one time (61). Once internalized the viral complex has the 
ability to evade RIG-1 and MDA-5 both critical intracellular PRRs to induce type-I 
interferons (62). The inhibition of these PRRs also dramatically alters the cytokine 
profile of the infected cell, shifting from a pro inflammatory state to an anti-inflammatory 
state (63, 64, 65, 66). Down stream of the RIG-1 and MDA-5 type-I interferons utilize 
the Jak/STAT pathway to stimulate interferon stimulated genes that are potent antiviral 
inhibitors. To overcome this the viruses, utilize NS5 to target the IFNAR for proteasomal 
degradation (67) or to target STAT2 for degradation stopping the signaling cascade 
(68,69). Cohort studies in Cuba and Taiwan indicate that patients with secondary DENV 
infection had higher levels of serum IL-10 levels (70,71). In contrast to early in infection 
which induces high levels of pro-inflammatory cytokines such as TNFα, IL-1β, and IL-6 
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secondary heterologous infection has demonstrated a slightly lower inflammatory 
phenotype, which could be attributed to the induction of IL-10 (72). The cell type in 
which the virus is infecting has significant effects on the amount of IL-10 induced. 
Monocytes have been shown to induce high levels of IL-10 while macrophages are poor 
inducers of IL-10 (66, 73). Once IL-10 is produced it decreases the production of IL-12 
and IFNγ both of which are potent inducers of activating adaptive immune cells with 
antiviral properties, must notably TH1 T cells and NK cells. Intracellular production of IL-
10 has been shown to increase the production of SOCS-3 which has been shown to be 
a biological marker for severe dengue viral infection (62). In conjunction with the 
immune modulation of the cells the viruses also influence other cellular functions 
including autophagy. DENV and ZIKV have both demonstrated the ability to increase 
autophagy and autophagasome formation in a Atg5 dependent manner (74, 75). This 
process may involve NS4a up regulating autophagy utilizing the PI3 kinase pathway 
(76).  
 
 
Chapter II 
Introduction Avian IgY 
Utilizing avian derived antibodies as alternative immunotherapies has developed into an 
attractive alternative for the treatment of animals and humans. Unique characteristics of 
avian antibodies can partially be contributed to the way in which the avian immune 
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system differs from the mammalian system. Like the mammalian immune system, the 
avian immune system possesses two major branches the innate and the adaptive 
systems. The innate system is the earliest system activated in response to a pathogen 
or antigenic stimuli. The innate response is made up of physical and chemical barriers 
to initially halt invading pathogens. These barriers also include biochemical responses 
such as defensins, complement, and lysozyme to name but a few. The innate system 
also harbors coordinated recruitment of specialized cells such as macrophages, 
granulocytes, thrombocytes, and natural killer cells. A distinct difference between 
mammalian innate system and avian system is the avian system lacks neutrophils, 
basophils, and eosinophils (77,78). Heterophils are the avian counterparts to the 
mammalian neutrophils. Heterophils, like neutrophils, are the fast acting cells of the 
innate system and are for the large part the first cell to the site of infection.  Like 
neutrophils heterophils have the ability to phagocytize invading pathogens. Heterophils 
do not have the capabilities to produce an oxidative burst to destroy phagocytized 
microbes, and the components of the granules contained within the cell differ from 
mammalian neutrophils. Cellular receptors are also responsible for the innate immune 
response. These class of receptors are term pattern recognition receptors (PRR) 
because they interact with conserved pathogen-associated molecular patterns 
(PAMPs). There are four primary classes of PRR, C-type lectins, TLRs, NLRs, and 
RLRs. C-type lectins are responsible for recognize extracellular PAMPs, while NLRs 
and RLRs are responsible for recognizing intracellular PAMPs. TLRs can recognize 
	 13	
both classes of PAMPs and are one of the most widely studied PRR within the field of 
avian immunology. Avian species possess TLR1/6/10, 2,3,4,5,7, and 8 which act 
essentially as homologs to the mammalian counter parts (79-90). It is apparent that 
chickens respond to the PAMP unmethylated CpG motif the classical TLR9 agonist, but 
no evidence has been found for TLR9 expression (91-93).  Chickens also possess two 
unique TLRs 15 and 21 (94, 95). Studies have shown that S. enterica challenge 
increased expression of chTLR15 specifically in the gut (95). Surprisingly chTLR21 has 
been shown to respond to unmethylated DNA containing CpG motifs, which could be 
the reason there has been no evidence of TLR9 in chickens because the function is 
already dominate by chTLR21 (96,97).  
Adaptive Immune system 
To assist in the maturation and development of the adaptive immune system the avian 
system possesses primary and secondary lymphoid organs. The primary lymphoid 
organs include the thymus, bone marrow, and an organ unique to avian species the 
Bursa of Fabricus (BF). The secondary organs include spleen, Harderian gland, 
germinal centers and other lymphoid tissues. Avian T cells have many of the structure 
and adaptive functions as mammalian T cells. Each T cell have a heterodimeric surface 
receptor (TCR) that is composed of two immunoglobulin domains that undergo 
extensive recombination to produce antigenic diversity (98). There are two heterodimer 
clusters the TCRαβ or TCR γ∆. A distinction of avian maturation is that unlike 
mammalian gene TCR clustering which is in one location avian species have two 
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locations. The second location most resembles IgH V segments of mammals (99). A 
second structural abnormality in the avian TCR development is the difference in CD3 
expression. Mammals possess four CD3 subgroups while the avian species only have 
two (100). To date TCR signaling of the avian system has no dissimilarities to the 
mammalian system indicating that the lack of CD3 diversity and increased TCR diversity 
does not influence downstream signaling drastically. The development of T cells 
spatially within the avian host is remarkably similar to that of mammals. Naïve T cells 
undergo development in the thymus. Differential expression in the periphery is dictated 
by the rate in which the T cells enter they thymus for development. The γ∆T cells are 
first to exit the thymus and circulate the periphery followed by the traditional αβT cells. 
The development of avian B-cells is drastically different from that of the mammalian 
system due to the presence of the BF. A common lymphoid progenitor cell expressing 
CCRA+ undergo Ig rearrangement which are then transported by the blood to the BF 
specially the mesenchyme (101, 102). Further Ig rearrangement and proliferation occurs 
in the Bursal mesenchyme and it is suggested that surface Ig expression is needed for 
the precursor cells to migrate to the Bursal follicles (103, 104). In order to remain in the 
bursal follicles, the precursor B-cells must express AID and expression of CXCR5 to 
bind to CXCL13. Gene conversion and a further round of proliferation occurs within the 
follicles that is driven by BAFF (105, 106). Upon further maturation the bursal follicle 
separates into the medulla and cortex. Upon antigen expression by a dendritic cell the 
cells specific for that antigen then migrate to the follicular cortex (85,86). Once within 
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the follicular cortex the antigen specific b cells undergo another round of gene 
conversion and proliferation. At this point the B-cells are able to leave the bursa and 
migrate to a secondary lymphoid organ such as the spleen. The B-cell can become 
activated by exposure to the antigen in which they are specific for along with T-cell help 
(107). After this point the antibody secretion process and plasma cell development is 
indistinguishable from mammalian development (108, 109).  
 
Immunoglobulin Maturation 
The maturation in which antibodies of the avian adaptive immune system undergo 
diverges significantly from their mammalian counter parts. There are three antibody 
isotypes, IgM, IgA, and IgY present in the avian immune system. These isotypes are 
mammalian homologs to IgM, IgA, and IgG (110). Antibody homologous to mammalian 
IgE and IgD have been proposed, but the data is inconclusive on identification (111). 
Avian IgY is distinguished from mammalian IgG due to the decay chain of the molecule 
is larger and antigenically different from IgG, and at the genomic level IgY is more 
similar to mammalian IgE than IgG (112). The structure of IgY is similar to IgG with two 
light (L) and two heavy (H) chains. The molecular mass of IgY is slightly larger than IgG 
167-250 kDa compared to 160 kDa respectively. The H chain has one variable (V) 
region and four constant (C) regions. The L chain is composed of one (V) and one (C) 
regions (113). Antibody diversity in the avian immune systems develops differently than 
in the mammalian system.  Loci rearrangements contribute slightly to diversity as both 
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the H and L chain have only one V gene. A major mechanism of diversity of antibody 
repertoire in the avian system is due to increased instances of somatic hyper 
conversion (114, 115). The avian immune system has developed three additional 
mechanisms to expand the antibody diversity: gene hyper conversion (115,116), V-J 
flexible joining (117), and somatic point mutations (118). Gene hyper conversion occurs 
in the BF, during which pseudo-V genes are processed and recombined into new 
variable regions resulting in increased immunoglobulin diversity depending on where 
the block of DNA from the V gene is spliced (119). This process is also applied to 
pseudo-V(D) genes (120). These genes are considered pseudo genes because they 
lack in promoter sequences necessary for transcription. (Reyanud CA). This unique 
feature allows for antibody diversity equivalent to the VDJ & VJ rearrangement of the 
mammalian system.  
Biochemical Properties of IgY 
Biochemically IgY is distinct from IgG partially due to the increased rigidity because of 
the lack of hinge region in the C domain of the H chain. This changes the the 
precipitation curve of IgY under high salt conditions (121). IgY is also more stable under 
acidic conditions maintaining it’s functionality between pH 4.0-11.0 (122, 123). IgY 
thermo satiability is comparable to IgG retaining functionality between 60-65ºC (122, 
123). IgY is also more resistant to proteases which may allow it to retain functionality as 
it passes through the stomach if orally administered (123, 124).  
Advantages of IgY Immunotherapy 
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There are distinct advantages to using IgY as an immunotherapy. The first is the 
phylogenetic distance between avian and mammalian species. This distance means 
that there is no cross-reactivity between IgY and mammalian IgG (125). This allows for 
the production of antibodies generated against conserved mammalian proteins (126). 
The phylogenetic distance also allows for greater antigenic recognition and affinity of 
IgY than mammalian IgG. It has been demonstrated that chicken IgY will bind to porcine 
antibodies with 3-5 times greater affinity than rabbit antibodies (126, 127). In a study 
antibodies generated against E7 oncoprotein of human papillomavirus type 16 IgY 
reacted against all of the peptides while IgG from rabbits recognized only two of the 
eight (128). The use of avian egg yolk as a source for antibody production greatly 
reduces the number of animals and strain on the animals. A single chicken yolk can 
produce 100-200 mg of total IgY (129), with 2-10% of total IgY being antigenic specific 
upon vaccination (130). IgY does not interact with mammalian complement systems, 
which in the case of DENV infection is a positive attribute. A study demonstrated that 
patients with Dengue hemorrhagic fever have elevated levels of activated complement 
components specifically C3a and C5a (131). Another critical characteristic of IgY is the 
lack of interaction with mammalian or known bacterial FcγR or Fc binding receptors. The 
lack of interaction with Fc receptors leads to premise that IgY will not induce ADE when 
encountering subsequent serotypes of Dengue or cross reactivity with ZIKV (134-137). 
Finally, IgY does not react with rheumatoid factor or human anti-mouse IgG antibodies 
(132, 133). This is important, because if the antibody reacts with the Fc part of 
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mammalian IgG, which is typical of patients with rheumatoid arthritis, the amount of 
antibody needed to neutralize the target antigen will be greatly increased.  
 
General uses of IgY in virology 
Due to the broader range of antigenic recognition and increased affinity to mammalian 
antigens IgY has been implemented in the development of a number of diagnostic tests 
and employed as immunotherapeutics. An enzyme-linked immunosorbent assay 
(ELISA) was developed to detect severe acute respiratory syndrome-associated 
coronavirus. This ELISA utilized IgY against the nucleocapsid protein as the detection 
antibody to increase the sensitivity of the assay. When the nucleocapsid protein IgY 
was compared directly against an IgG monoclonal antibody the detection limit of the 
assay was increased dramatically from 20-200 pg/mL to 10 pg/mL (138). To increase 
the power of IgY technology as a diagnostic tool for severe acute respiratory syndrome-
associated coronavirus phage display generated monoclonal IgY antibodies with a 
single-chain variable fragment. Using this phage display system monoclonal IgY 
antibodies were generated against the spike protein which can be applied for rapid 
diagnostics and can be applied therapeutically (139). The diagnostic capabilities of IgY 
is also extended to hepatitis viruses. An indirect immunofluorescence assays was 
developed using IgY as the primary antibody to recognize hepatitis A virus in frozen 
liver sections (140). This technique is advantages because it is able to detect minute 
amount of virus where IgM levels are too low to detect in the serum and the virus is 
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unable to be detected by molecular means (141,142). The same anti-hepatitis IgY is 
used is a immunoenzymatic assay to measure the total anti-hepatitis antibody levels. 
This immunoenzymatic assay demonstrated increased sensitivity and specificity 
compared to the commercially available kit. This test could potentially then be used in 
place of the commercial kit or an alternative to the traditional IgG immunoassays. (143). 
This same principal was extended to hepatitis B virus as well. The purification process 
of the anti-hepatitis B virus was more extensive, but the resulting product could be used 
as a secondary antibody in a rapid detection ELISA (144, 145). Another promising area 
of assay development is utilizing IgY in immunochromatographic assays (ICAs). ICAs 
are also called lateral flow dipstick immunoassays which are typically used for rapid 
identification of a pathogen or substrate. Due to the short incubation time for these tests 
they are commonly referred to as point of care tests as well. A ICA was developed for 
canine parvovirus, which utilized a oligoclonal IgY preparation generated against canine 
parvovirus virus-like particle. When the IgY ICA was compared with PCR identification 
the ICA exhibited 94.17% conformity to the PCR results (146). Similar ICAs were also 
developed against soft-shell turtle systemic septicemia spherical virus and swimming 
crab reovirus (147, 148).  
IgY as an Immunotherapeutic 
Avian IgY has attracted considerable attention as an alternative to antibiotic therapy due 
to the increasing rise of antibiotic resistant pathogens, specifically those which infect the 
gastrointestinal tract. This trend hence has extended to viral pathogens of the 
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gastrointestinal tract as well as systemic viral infections. One such example is the 
production of anti-norovirus P particle to combat norovirus infection. The authors 
demonstrated efficacy of their IgY preparation in vitro and suggested this could be used 
as a passive immunotherapy for high risks groups such as young children and the 
elderly (149). Building upon that study the production of a dual IgY preparation was 
created to not only combat the P particle of norovirus, but also the VP8 spike protein of 
rotavirus. The dual IgY preparation also demonstrated in vitro efficacy with NT50 of 
0.25mg/ml for rotavirus and a blocking titer 50 (BT50) of 1: 1,300 for norovirus A and 1: 
1,200 for norovirus B (150). Anti-rotavirus IgY has been utilized in newborn cattle which 
dramatically reduced the viral shedding and severity of diarrhea compared to controls 
(151, 152). A randomized double-blind clinical trial with 79 children with a history of 
rotavirus induced diarrhea were treated with freeze dried egg yolk IgY or placebo, and 
both groups received oral rehydration therapy. The group receiving IgY had significantly 
reduced viral shedding and the stool output frequency was reduced, only 1 day after 
treatment however (153). These results were mirrored in another clinical trial testing 
Rotamix IgY, this trial the severity of diarrhea was also reduced in the treated group 
compared to the placebo group. Viral shedding and oral hydration fluid administration 
needed was decreased in the treated group (154). Goose derived IgY has 
demonstrated efficacy against systemic viral infections. Goose derived IgY generated 
against the DNA vaccine of hantavirus produced a robust humoral immune response 
and the purified anti-hantavirus was able to protect Syrian hamsters from a lethal 
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challenge of hantavirus (155). In another study geese were immunized with inactivated 
DENV2 and the humoral immune response was monitored. The subsequent IgY 
preparation was then tested for it’s neutralization capacity in vitro and in vivo. The NT50 
of the anti-DENV2 IgY was 2.5 µg/ml. Mice treated with anti-DENV2 IgY survived a 
lethal challenge of DENV2 in a dose dependent manner with 1mg having 100% survival, 
500µg 66%, and 50µg 33% survival (156). In each of these studies epitope mapping 
was done on the newly developed IgY preparations and in each instance novel 
antigenic epitopes were found in both viruses. This demonstrates the epitope diversity 
that can be achieved utilizing the IgY platform. Upon further study enriching the IgY 
preparations with novel epitopes could bring light to new neutralizing epitopes. It will 
also allow for enrichment of IgY antibodies of known neutralization epitopes from 
previously described monoclonal IgG panels.  The previous studies demonstrate the 
versatile and robust nature of utilizing IgY as not only a diagnostic tool, but also as an 
alternative immunotherapeutic.  
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Chapter III 
Zika Virus Vector Competency  
Abstract  
Zika virus is an emerging arbovirus of humans in the western hemisphere. With its 
potential spread into new geographical areas, it is important to define the vector 
competence of native mosquito species. We tested the vector competency of Aedes 
vexans (Meigen) from the Lake Agassiz Plain of northwestern Minnesota and 
northeastern North Dakota. Aedes aegypti (L.) was used as a positive control for 
comparison. Mosquitoes were fed blood containing Zika virus and 2 weeks later were 
tested for viral infection and dissemination. Aedes vexans (n=60) were susceptible to 
midgut infection (28% infection rate) but displayed a fairly restrictive midgut escape 
barrier (3% dissemination rate). Co-fed Ae. aegypti (n=22) displayed significantly higher 
rates of midgut infection (61%) and dissemination (22%). To test virus transmission, 
mosquitoes were inoculated with virus and 16–17 d later, tested for their ability to 
transmit virus into fluid-filled capillary tubes. Unexpectedly, the transmission rate was 
significantly higher for Ae. vexans (34%, n=47) than for Ae. aegypti (5%, n=22). The 
overall transmission potential for Ae. vexans to transmit Zika virus was 1%. Because of 
its wide geographic distribution, often extreme abundance, and aggressive human biting 
activity, Ae. vexans could serve as a potential vector for Zika virus in northern latitudes 
where the conventional vectors, Ae. aegypti and Ae. albopictus Skuse, cannot survive. 
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However, Zika virus is a primate virus and humans are the only amplifying host species 
in northern latitudes. To serve as a vector of Zika virus, Ae. vexans must feed 
repeatedly on humans. Defining the propensity of Ae. vexans to feed repeatedly on 
humans will be key to understanding its role as a potential vector of Zika virus. 
  
Introduction 
Zika virus (family Flaviviridae) is a mosquito-borne virus of primates in sub-Saharan 
Africa that has spread rapidly within the past decade to cause serious epidemics 
throughout the western Pacific and Latin America (157). Several features of Zika virus 
make its spread particularly troubling. In addition to being transmitted by infective 
mosquitoes, Zika virus can also be transmitted sexually (158). No other arbovirus is 
known to be sexually transmitted. In most cases, Zika virus infections in humans do not 
produce life-threatening illness, but in some instances, Zika virus infections can lead to 
a neuropathic condition known as Guillain-Barre´ syndrome, and in pregnant women, 
Zika viral infection can infect the fetus causing a brain abnormality known as 
microcephaly in the unborn child (159). Sylvatic circulation of Zika virus in Africa 
involves primarily monkeys and several species of tree hole and container-breeding 
Aedes spp., including Aedes africanus (Theobold) (160), Aedes luteocephalus 
(Newstead), and Aedes vittatus Bigot (161) Urban circulation involves a human–
mosquito–human cycle with Aedes aegypti (L.) as the primary vector (162). Other 
mosquito species have been implicated as competent vectors of Zika virus, most 
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notably Aedes albopictus (Skuse) (163), and to a lesser extent, Aedes hensilli Farner 
(164), and some (165) but not allstrains within the Culex pipiens L./Culex 
quinquefasciatus Say complex (166-170). In this report, we tested Aedes vexans 
(Meigen) from the upper Great Plains for their ability to transmit Zika virus. Figure 1 
demonstrates the multi facet transmission cycles and how they are interconnected  
  
Figure 1: A.) Enzootic transmission cycle of Zika virus. B.) Epidemic 
transmission cycle of Zika virus  
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Materials and Methods 
Mosquitoes 
Host-seeking mosquitoes were collected using a Mosquito Magnet X trap (kind gift of 
Metropolitan Mosquito Control District, St. Paul, MN) baited with bottled CO2 released at 
a flow rate of ca. 500 ml per minute.  The trap was operated overnight at rural residences 
in Polk County, MN (31 July 206) and Grand Forks County, ND (22 September 2016).  
Both sites are located within the Lake Agassiz Plain eco-region of northwestern 
Minnesota and northeastern North Dakota.  The next morning, the trap was transported 
to the laboratory and mosquitoes were released into a large, cubic-meter screened cage.  
Mosquitoes were maintained for several days on cotton pads soaked in 10% sugar water 
and 0.05% antibiotic solution.  Antibiotics were given to eliminate variation in bacterial 
loads within the alimentary tracts of wild-caught mosquitoes and thus minimize any 
potential confounding effects that midgut bacteria may exert on the infectivity of 
experimentally administered virus (171).  As a positive control for vector competence, an 
Aedes aegypti colony (Costa Rica strain, F39) was established from eggs obtained from 
BEI Resources.  Female Ae. aegypti mosquitoes were likewise maintained for several 
days on the glucose-antibiotic solution prior to testing.  
 
Virus  
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The strain of Zika virus used in this study was originally isolated from a patient in Puerto 
Rico in 2016 (PRVABC59). Viral stocks were prepared after two passages of the isolation 
onto Vero cells maintained at 37°C.  Viral titer was estimated via a plaque assay, 10-fold 
serial dilutions were inoculated onto Vero cells overlaid with 1% methylcellulose and 
complete DMEM, which were then incubated for 7 days.  The overlay was then removed 
and the monolayer was fixed with 10% formaldehyde and stained with crystal violet.  
Infection was measured by the observance of cytopathic effect and the resulting titer was 
expressed as plaque-forming units per milliliter (PFU/ml).  The viral stock was diluted 1:1 
with heat inactivated fetal bovine serum then divided into 1 ml aliquots and stored at -
80°C.  
 
Oral infection of mosquitoes  
Prior to infection, mosquitoes were transferred to 3.8-liter cylindrical cardboard cages (ca. 
50 per cage) each fitted with a screened top secured with tape and a single high-security 
double-layered dental dam access portal.  Infectious blood consisted of Zika virus culture 
media mixed 1:1 with de-fibrinated cow blood (Pel-Freez Biologicals, Rodgers, AK USA).  
The first trial (Minnesota mosquitoes plus Ae. aegypti) used thawed virus fed to 
mosquitoes at an estimated blood meal concentration 9.2 x 106 PFU/ml.  The second trial 
(North Dakota Ae. vexans) used fresh virus grown on Vero cells prior to mosquito feeding 
and with an estimated blood meal concentration of 2.0 x 105 PFU/ml.  Blood meals were 
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administered via water-jacketed membrane feeders (circulating water at ca. 38°C) fitted 
with de-salted pork sausage casing.  Mosquitoes were given 1 hour to feed, after which 
unfed mosquitoes were removed.  Cages containing engorged mosquitoes were placed 
within transparent plastic tubs and maintained on glucose-antibiotic solution for 14 days 
in a biosafety level-2 insectary with restricted access and environmental settings at 28°C 
and 16:8 L:D light cycle.  At 14 days, mosquitoes were killed by freezing at -20°C for > 2 
hours.  For each mosquito, the legs were pulled off and the bodies (=infection) and 
mosquito legs (=disseminated infection) were ground separately in 200 µl grinding 
solution (M-199 + 5% calf serum + 0.5% antibiotics).   
 
Parenteral infection and salivary transmission  
Virus was inoculated into mosquitoes to test their ability to transmit virus orally.  
Mosquitoes were immobilized by chilling (1 minute in -20°C freezer) in batches of 5 to 15 
each and placed on a chill table (BioQuip, Rancho Dominguez, CA).  Mosquitoes were 
injected intrathoracically with 0.2 µl of media containing 1.8 x 107 PFU/mL using a glass 
needle powered by a microinjection pump (TriTech Research Inc., Los Angeles CA).  
Following injection, mosquitoes were placed into 0.5 liter cylindrical cardboard cages and 
maintained as described above.  On 16 to 17 days after injection, mosquitoes were tested 
for their ability to secrete virus in their saliva (172).  To do this, 3 to 5 mosquitoes at a 
time were chilled, legs amputated and then placed on a strip of double-stick tape running 
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along the edge of a glass plate.  Mosquito were carefully positioned on the plate so that 
their proboscises were free and hanging over the edge.  Immediately after mosquitoes 
were in position, a small amount of malathion insecticide (0.4 µl of 0.14%AI in acetone) 
was applied to the thorax of each mosquito to stimulate salivation (173).   After 10 to 15 
minutes, this plate was abutted against a second glass plate to which capillary tubes 
containing ca. 20 µl of M-199 media plus 10% calf serum were affixed.  Each mosquito 
proboscis was carefully inserted into a liquid-filled capillary tube and mosquitoes were 
given 20 to 30 minutes to salivate during which they were examined periodically under a 
stereoscope for probing behavior, salivation and ingestion of capillary tube contents.  
After the allotted time, capillary tubes were collected and the contents expelled into 
individual microfuge tubes containing 50 µl of media.  Likewise, the mosquitoes were 
removed and placed into individual microfuge tubes for processing.  Tubes were labeled 
so that expectorate samples could be matched to the individual mosquitoes from which 
they had been collected. 
 
Zika virus detection 
Viral RNA was detected using reverse transcriptase polymerase chain reaction (RT-PCR) 
techniques.  Frozen triturates of mosquito bodies and legs were thawed, centrifuged at 
14,500 rpm for 5 minutes and 140µL of supernatant was extracted for RNA using Qiagen 
QIAamp Viral RNA Mini Kits according to manufacturer’s instructions.  Real time PCR 
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was conducted using Qiagen one-step RT-PCR kit with primers specific for the envelope 
gene. Probe sequence:5’-56FAM/ACGCCTAAT/ZEN/TCACCAAGAGCGGAA/3IABkFQ-
3’ Primer1: 5’-TCCTAAGCTTCCAAAGCCTCCCAA-3’ and Primer2: 5’-
TATCAGTGCATGGCTCCCAGCATA-3’.  Cycle parameters were (i) 30 min at 50°C, (ii) 
15 min at 95°C, (iii) 40 cycles of; 1 min at 94°C, 1 min at 54°C, 1 min at 72°C, and 10 min 
72°C.  Reactions were performed using CFX96™ IVD Real-Time PCR Systems and 
accompanying software to determine cut-off values based on a minimum of 2 negative 
controls (water only) and two positive controls (Zika viral culture extracts) per assay.   
 
 
 
Results 
Susceptibility to Oral Infection and Viral Dissemination 
Membrane feeding success was higher for colonized Ae. aegypti (69%, n=39) than for 
wild-caught Ae. vexans (43%, n=168; χ2 =8.82, P=0.003). Aedes aegypti had 
significantly higher rates of viral infection and dissemination than Ae. vexans (Fisher 
exact tests, P<0.024). Seventeen of 60 Ae. vexans tested (28%) became infected and 
two (3%) developed disseminated infections, indicating a moderately severe midgut 
escape barrier for Zika virus in this species. Eleven of 18 Ae. aegypti tested (61%) 
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became infected and four (22%) developed disseminated infections (Figure 2). 
However, the proportion of infected mosquitoes having disseminated infections did not 
differ statistically between Ae. aegypti (4 of 11) and Ae. vexans (2 of 17; Figure 2; 
Fisher exact test, P.0.14). Interestingly, there were no differences in infection or 
dissemination rates between Ae. vexans fed fresh versus thawed virus (P’s>0.59, 
Fisher exact tests), even though thawed virus had nearly 100-fold higher titer (Table 1). 
This supports earlier findings that freshly cultured Zika virus is more infective to 
mosquitoes than frozen virus that is thawed just prior to feeding to mosquitoes (174). 
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Figure 2: Midgut and disseminated infection of Ae. vexans and Ae. aegypti. 
A.) Percent midgut infection of Ae. vexans and Ae. aegypti mosquitoes exposed to 
a blood meal containing Zika virus. B.) Percent disseminated infections from the 
midgut of Ae. vexans and Ae. aegypti with midgut infections of Zika virus.  
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Mosquito 
Species 
Mosquito 
Origin 
Virus and 
Blood meal 
Concentration 
% 
Infectiona 
% 
Disseminationb 
% 
Dissemination 
/ Infectionc 
Aedes 
aegypti 
Colonized; 
Costa Rica 
strain (BEI 
Resources) 
Thawed 
9.2 x 106 
PFU/ml 
61 
(11/18) 22 (4/18) 36 (4/11) 
Aedes 
vexans 
Wild-
caught; 
Grand 
Forks Co., 
ND 
Fresh 
2.0 x 105 
PFU/ml 
28 (9/32) 3 (1/32) 11 (1/9) 
 
Wild-
caught; 
Polk Co., 
MN 
Thawed 
9.2 x 106 
PFU/ml 
29 (8/28) 4 (1/28) 12 (1/8) 
Aedes 
trivittatus 
Wild-
caught; 
Polk Co., 
MN 
Thawed 
9.2 x 106 
PFU/ml 
0 (0/6) 0 (0/6) 0 (0/0) 
Culex 
tarsalis 
Wild-
caught; 
Polk Co., 
MN 
Thawed 
9.2 x 106 
PFU/ml 
0 (0/3) 0 (0/3) 0 (0/0) 
Culiseta 
inornata 
Wild-
caught; 
Polk Co., 
MN 
Thawed 
9.2 x 106 
PFU/ml 
0 (0/1) 0 (0/1) 0 (0/0) 
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Virus Transmission by Innoculated Mosquitoes 
 
To test for salivary gland barriers, Ae. vexans and Ae. aegypti were inoculated with virus 
and, after 16-17 days incubation, were stimulated to salivate into capillary tubes.  When 
the bodies of inoculated mosquitoes were assayed, all 47 inoculated Ae. vexans were 
positive (100%) and 22 of 23 inoculated Ae. aegypti (96%) were positive.  Saliva samples 
were tested for virus from body-positive mosquitoes.  Thirty-three of 47 body-positive Ae. 
vexans (70%) were observed to either salivate or imbibe fluid during the salivation period, 
whereas only 5 of the 22 body-positive Ae. aegypti (23%) were observed to do so.  
Sixteen of the 47 Ae. vexans (34%) transmitted virus, whereas only one of the 22 Ae. 
aegypti (5%) transmitted virus (Table 2) (Fisher exact test, p=0.06).  Whether or not a 
mosquito was observed to salivate into and/or imbibe fluid from its capillary tubes had no 
bearing on whether or not virus was transmitted.  Of the 16 Ae. vexans that transmitted 
virus, 12 (75%) were observed to salivate and/or imbibe and 4 (25%) were not.  
Conversely, of the 31 Ae. vexans that did not transmit virus, 21 (68%) were observed to 
Table 1.  Infection and dissemination of Zika virus in wild-caught and colonized 
mosquitoes 14 days after ingesting defibrinated blood containing virus. 
aPercentage of mosquitoes containing virus in their bodies (number positive / 
number tested). 
bPercentage of mosquitoes containing virus in their legs (number positive / number 
tested). 
cPercentage of infected mosquitoes containing virus in their legs (number positive / 
number tested). 
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salivate and/or imbibe and 10 (28%) were not (χ2=0.27, p=0.61).  The single Ae. aegypti 
that transmitted virus was not observed to salivate nor imbibe fluid.  Thus stereoscopic 
observation of mosquitoes during in vitro salivation tests was not useful in detecting actual 
expectoration of saliva. 
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Mosquito Species Mosquito Origin % Transmissiona 
Aedes aegypti Colonized; Costa Rica strain (BEI Resources) 5 (1/22) 
Aedes vexans Wild-caught; Grand Forks Co., ND 34 (16/47) 
Table 2.  Transmission of Zika virus by mosquitoes 16 to 17 days after being inoculated 
intrathoracically with 0.3 µl of media containing 1.8 x 107 plaque-forming units per 
milliliter of virus. 
 aPercentage of mosquitoes with a disseminated viral infection that expectorated virus 
into fluid-filled capillary tubes following a topical application of 0.4 µl acetone 
containing malathion (0.14% AI) to induce salivation. 
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Discussion 
 
This study indicates that Ae. vexans from the upper Great Plains is physiologically 
capable of becoming orally infected and transmitting Zika virus. Aedes vexans displayed 
moderate to severe midgut and midgut escape barriers to virus infection and 
dissemination, respectively. However, once disseminated infections were established, 
the transmission rate of Zika virus by Ae. vexans (34%, n.47) was comparable to 
transmission rates reported at similar incubation periods (i.e., 14 d) for some (but not 
all) strain combinations of Zika virus and Ae. aegypti (i.e., 175 [33%, n.12], 176 [21%, 
n.14], 177 [42%, n.33], 178 [5%, n.189], 179 [31%, n.36]). Aedes vexans is the first 
indigenous North American mosquito species found capable of transmitting Zika virus 
under laboratory conditions. Several other mosquito species have been shown in 
laboratory studies to be refractory to Zika virus, including Aedes triseriatus (Say) (Aliota 
et al. 2016b), Aedes taeniorhynchus (Wiedemann) (170), and Culex tarsalis (Coq.) 
(174) from North America, Aedes polynesiensis Marks from French Polynesia (177), 
and Aedes notoscriptus (Skuse), Aedes procax (Skuse), Aedes vigilax (Skuse), Culex 
annulirostris Skuse, and Culex sitiens Wiedemann from Australia (180). The primary 
urban vectors of Zika are Ae. aegypti and Ae. albopictus. As Zika virus spread from 
Africa into Asia, Oceania, and the Western Hemisphere, the virus encountered novel 
populations and 
strains of these vector species. It is now clear from recent vector competency studies 
that the efficiencies by which Ae. aegypti and Ae. albopictus transmit Zika virus varies 
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greatly depending on the strains of mosquito and virus examined. In our study, the rates 
of viral infection (61%) and dissemination (22%) for Zika virus in our Ae. aegypti strain 
were comparable to other strain combinations examined, yet the transmission rate (5%, 
Table 2) was uncharacteristically low. We had purposely selected our “positive control 
system”—i.e., a Latin American strain of Ae. aegypti (Costa Rica) and a Caribbean 
isolate of Zika virus (Puerto Rico)—based on the assumption that the close geographic 
proximity of origin between mosquito strain and virus isolate would result in optimal 
virus transmission. This proved not to be the case. But this is not the first example of 
incompatibility between geographically proximate strains. Interestingly, two separate 
strains of Ae. aegypti from Senegal have been reported to have severely limiting midgut 
escape barriers and insurmountable salivary gland barriers to the native Sengalese 
strain of Zika virus (161). Thus, Ae. aegypti is probably not the vector for Zika virus in 
Senegal. Conversely, a strain of Ae. aegypti from Mexico produced a significantly higher 
rate of disseminated infection with a Zika virus strain from Senegal (60%, n.48) than 
with Zika virus isolated from a patient in Puerto Rico (42%, n.48; 
174). These studies indicate that the combination of mosquito and virus strains in the 
Ae. aegypti–Zika system greatly influences vector competency although the outcome 
cannot be predicted based on geographic origins of strains and isolates. Aedes aegypti 
is widely distributed throughout tropical latitudes and analogously, Ae. vexans is widely 
distributed throughout temperate and subarctic latitudes. Thus, it may be anticipated 
that Ae. vexans may also display geographic heterogeneity in vector competence to 
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Zika virus. Such heterogeneity has been shown to occur with Ae. vexans and Rift Valley 
fever virus, where southern populations of North American Ae. vexans are susceptible 
but northern populations are not 
(181-183). Beyond its ability to transmit the virus, there are other characteristics of Ae. 
vexans that could contribute to its role as a potential vector of Zika virus in the Northern 
Hemisphere. First, Ae. vexans is an aggressive, nearly cosmopolitan Holarctic mosquito 
species with a long flight range (184-186). It feeds primarily on large mammals and 
readily attacks humans during both day and night (187). Second, Ae. vexans is 
extremely prolific and often cited as the most abundant species found in mosquito 
surveys conducted throughout the northern hemisphere, including central Canada 
(188), most of the United States (189), France (190), Germany (191), Czech Republic 
(192), Slovakia (193), Hungary (194), Croatia (195), Russia (196), Iran (197), South 
Korea (198), and China (199). Third, Ae. vexans has been shown in laboratory studies 
to be a competent vector for several arboviruses, including West Nile virus (200), 
eastern equine encephalomyelitis virus (201), Saint Louis encephalitis virus (202), Rift 
Valley fever virus (203), Tahyna virus (204), and Geta virus (205). Thus, it would seem 
that Ae. vexans could potentially play a role in transmitting Zika virus if the virus were to 
be introduced into more northerly latitudes of North America or Eurasia where the 
primary vectors, Ae. aegypti and Ae. albopictus, are absent. On the other hand, Zika 
virus is a virus of primates. Outside the tropics, humans are essentially the only 
amplifying host. Thus, for Ae. vexans to be a vector of Zika virus in northern latitudes, it 
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would have to feed on a viremic human, survive the extrinsic incubation period of the 
virus, and then feed again on a human. Using mark–release–recapture techniques, 
Jensen and Washino (1994) estimated the field survivorship of Ae. vexans in California 
to be fairly low (daily survival.0.70) compared to typical values reported for Ae. aegypti 
(e.g., 0.80 to 0.95). Low field survival would reduce the overall vectorial capacity of Ae. 
vexans. Nevertheless, densities of host-seeking Ae. vexans can be extreme, even in 
residential areas (206). Prodigious numbers may compensate for low daily survival and 
weak vector competence, and thus elevate the importance of Ae. vexans as a vector for 
zoonotic arboviruses in some regions (172). But again, the transmission pattern of Zika 
virus in the north would undoubtedly be human-to mosquito-to-human. Thus, 
information regarding the propensity of Ae. vexans to feed repeatedly on humans is key 
in evaluating its potential as a vector of Zika virus. In the rural Midwest, Ae. vexans feed 
primarily on deer (207). But the primary bloodmeal sources for Ae. vexans are less well-
defined in suburban and urban areas where human density, and hence human 
availability as blood sources, typically exceeds that of deer and other large mammals. 
To help define the actual vector potential of Ae. vexans for Zika virus in North America, 
mosquito surveillance programs could include pools of field-collected Ae. vexans as part 
of their Zika virus testing— particularly in the southeast USA where Ae. vexans and Ae. 
aegypti co-occur and the threat of local virus amplification exists. This may reveal 
whether or not Ae. vexans mosquitoes are being naturally exposed to Zika virus. 
Additional vector competence studies with Ae. vexans (e.g., comparing geographic 
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strains, defining extrinsic incubation period, transovarial transmission, etc.) are 
warranted because of this species’ expansive distribution, considerable dispersal 
capability, often excessive abundance, and propensity to attack humans. Other 
Holarctic anthropophagic mosquito species should also be examined.  
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Chapter IV 
Avian IgY as an Immunotherapy for Zika Virus  
Abstract  
Zika virus (ZIKV) is a newly emerged pathogen in the Western hemisphere. It was 
declared a global health emergency by the World Health Organization in 2016. There 
have been 223,477 confirmed cases including 3,720 congenital syndrome cases since 
2015. ZIKV infection symptoms range from asymptomatic to Gullain-Barré syndrome 
and extensive neuropathology in infected fetuses. Passive and active vaccines have 
been unsuccessful in protecting from or treatment for ZIKV infection due to antibody 
dependent enhancement (ADE). ADE causes an increased viral load due to increased 
monocyte opsonization by non-neutralizing low avidity antibodies from a previous 
dengue virus (DENV) infection or previous exposure to ZIKV. We have previously 
demonstrated polyclonal avian IgY generated against whole-killed DENV-2 ameliorates 
DENV infection in mice while not inducing ADE. This is likely due to the inability of the 
Fc portion of IgY to bind to mammalian Fc receptors. We have shown here that ZIKV 
oligoclonal IgY is able to neutralize the virus in vitro and in IFNAR-/- mice. The 
concentration of ZIKV-specific IgY yielding 50% neutralization (NT50) was 25µg/mL. 
Exposure of the ZIKV, prior to culture with ZIKV-specific IgY or 4G2 flavivirus envelope 
IgG demonstrated that the ZIKV-specific IgY does not induce ADE. ZIKV IgY was 
protective in vivo when administered following a lethal ZIKV challenge in a 3 week old 
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IFNAR-/- mice. We propose polyclonal ZIKV-specific IgY may provide a viable passive 
immunotherapeutic for ZIKV infection without inducing ADE.  
 
Introduction 
Flaviviruses are a major health concern throughout the world. A newly emerged 
flavivirus that has major health implications is Zika virus (ZIKV). A majority of ZIKV 
infections are asymptomatic in the host. Severe ZIKV symptoms extend to neurological 
diseases including Gullian-Barre Syndrome (GBS) (208,209) and congenital Zika 
syndrome (CZS). CZS can be further differentiated into microcephaly, brain 
abnormalities, and other severe birth defects (210-214). In 2016 the world health 
organization (WHO) declared ZIKV a world health threat and pushed for the 
development of vaccines and antivirals to combat ZIKV infection (215).  
ZIKV is a member of the Flaviviridae family which also includes dengue virus 
(DENV), west nile virus (WENV), Japanese encephalitis virus (JEV), yellow fever virus 
(YFV), and tick-borne encephalitis virus (TBEV). ZIKV is primarily spread by Aedes 
species of mosquito (160). Recently our lab has identified that Aedes vexans is also a 
potential competent vector which extends the geographical range of infection from 
tropical to temperate climates as well (216). In the absence of quality vector control in 
the countries affected by ZIKV the development of new antivirals and vaccine 
candidates is required to control the spread of ZIKV.  
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 Severe flavivirus infection can be attributed to cross reactive inflammatory T cells 
and non-neutralizing antibodies that induce antibody dependent enhancement (ADE) 
(217,218). ADE occurs via antibodies from a primary infection binding to a heterotypic 
flavivirus. The viral immune-complex is then recognized by the FcγR on a dendritic cell 
or macrophage and binds via the Fc portion of the antibody. This complex is then 
internalized in the endosome where the pH decreases as the endosome matures. This 
drop in pH lowers the affinity of the antibody and virus allowing the virus to dissociate 
from the antibody. Once the virus has dissociated from the antibody normal viral 
replication is commenced by the fusion of the envelope to the membrane of the 
endosome releasing the viral nucleic acid (219).  
 To date there is an unmet need for an effective antiviral therapeutic for ZIKV 
infection. Recently, one area of research that is showing promising results is the 
utilization of truncated antibodies that lack the Fc portion. Settler et al. demonstrated 
that truncated monoclonal antibodies were able to neutralize primary ZIKV infection and 
a secondary DENV infection without inducing ADE. They further go on to demonstrate 
that the truncated monoclonal antibodies were able to protect IFNAR-/-  mice challenged 
with a lethal dose of ZIKV (219). We hypothesize that avian IgY, the avian homolog of 
IgG, will be an effective therapeutic against flavivirus infections based on the unique 
characteristic that full length IgY does not bind to mammalian FcγR. Previously we have 
demonstrated that Dengue specific IgY was effective at neutralizing lethal infections 
with DENV2 without inducing ADE (156).  
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 IgY is the avian homologue of mammalian IgG and shares characteristics with 
mammalian IgG and IgE. IgY is the predominant isotype in sera after the initial 
production of IgM, and is the primary antibody produced upon a secondary response 
(110,111). IgY is found in two isoforms, in the serum of water fowl, full-length IgY that 
contains two constant regions and an alternatively spliced IgY that lacks these two 
constant regions (110,115). The alternatively spliced IgY would be the avian structural 
equivalent of the truncated IgG proposed by Settler et al. Previous studies from our 
laboratory have demonstrated the efficacy of the utilization of IgY in viral infections. We 
first demonstrated that Andes virus-specific IgY provided protection from Hantavirus 
pulmonary syndrome in a hamster model (155). Most recently we have demonstrated 
that DENV specific IgY was able to protect AG129 mice from a lethal dose of DENV2 
(156).  
 There are many benefits for the utilization of IgY as an immunotherapy in 
mammals, first the phylogenic distance between the avian species producing the 
antibody and the recipient mammalian host allows for a much broader range of 
antigenic recognition.  This is due to the increased avidity for mammalian antigens and 
the ability to recognize antigens that normally would not be immunogenic in a 
mammalian host. Increased antigenic recognition and avidity of IgY is attributed to the 
unique antibody maturation process. During IgY maturation gene hyper conversion 
allows for pseudo-V genes to recombine with existing variable regions of the Ig genes to 
produce mature B-cells. The second reason is V-J flexible joining; this is when partial 
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conversions of rearranged segments are replaced by pseudo-V(D) genes. The third 
mechanism to produce diversity is the large amount of somatic hyper mutations that is 
undergone (110-116). Another critical characteristic of IgY is the lack of interaction with 
mammalian or known bacterial FcγR or Fc binding receptors. The lack of interaction with 
Fc receptors leads to premise that IgY will not induce ADE when encountering 
subsequent serotypes of Dengue or cross reactivity with ZIKV. Further, IgY does not 
interact with mammalian complement systems, which in the case of DENV infection is a 
positive attribute. A study demonstrated that patients with Dengue hemorrhagic fever 
have elevated levels of activated complement components specifically C3a and C5a 
(220). Not only are the immune characteristics of IgY attractive but the industrial 
production potential also makes IgY an attractive therapeutic candidate. Due to the fact 
that IgY can be isolated from the eggs of laying geese or hens, this allows for a non-
invasive way of harvesting an immunotherapy compared to production in a mammalian 
host such as rabbits. The antibody yield is also much greater per month due to this non-
invasive aspect, 1,300 to 1,500 mg of IgY can be produced from one bird per month 
compared to 200 mg from a mammalian source (221). There are currently large-scale 
production methods and sites functional at this time making IgY an economically 
feasible therapeutic.  
 In this study we demonstrate the efficacy of goose derived anti-ZIKV IgY in vitro 
and in vivo. Specifically, ZIKV IgY produce protection greater than 50% reduction in a 
plaque reduction neutralization test, and ZIKV IgY did not produce ADE in vitro. Finally, 
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we demonstrate that ZIKV specific IgY can protect 3 week old IFNAR-/- mice from a 
lethal ZIKV challenge.  
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
Ethics Statement 
Research was conducted in compliance with the Animal Welfare Act and adheres to the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health. The protocol was approved by the Institutional Animal Care 
and Use Committee at the University of North Dakota and the Institutional Biosafety 
Committee.  
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Geese 
The geese (Anser domesticus 25 months old) used to produce IgY are an inbred hybrid 
of a combination of German Embden, the Royal Chinese, and the Royal English breeds. 
The animals were housed at the Specific Pathogen Free facility on the Schiltz Goose 
Farm, Inc. The barn also housed a clean room for ISO egg production which was 
equipped with HEPA filtration to remove circulating particles. Only authorized personnel 
were allowed into the facility.  
 
Mice 
B6.129S2-Ifnar1tm1Agt/Mmjax (IFNAR-/-) were purchased from Jackson Laboratory 
MMRRC stock #32045 (222). Mice were maintained in clean rooms in the Center for 
Biomedical Research Center, UND.  
 
Viruses and Cell Lines 
Zika virus PRVABC59 was propagated in Vero cells (ATCC). Briefly Vero cells at 80% 
confluency in 6 well plates were infected at an MOI of 0.1 and allowed to adhere for one 
hour at 37ºC with 5% CO2. The cells were washed with DMEM containing 10% fetal 
bovine serum (FBS) (Atlanta biologicals, Atlanta, GA), Penicillin/Streptomycin (Corning, 
Corning, NY), and 2.5mM HEPES, (cDMEM). 3ml of cDMEM was replaced in the wells 
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the plates were incubated at 37ºC 5% CO2 for five days. The cell supernatant was 
centrifuged at 4,000x g for 5 min at 4 ºC to remove cell debris. The clarified cell 
supernatant was diluted 1:2 in heat inactivated FBS and frozen at -80ºC. The resulting 
viral stocks were quantified via plaque assay.  
 
Vaccination 
The vaccination schedule to produce DENV specific IgY was previously described. Zika 
virus PRVABC59 was propagated in Vero cells to a titer of 3.8x105 PFU/ml. The cell 
supernatant was centrifuged 4,000x g 10 min at 4 ºC to remove cell debris. The 
resulting supernatant was exposed to 5.23 Mrad of gamma irradiation. The resulting 
viral stock was shown to be inactivated via plaque assay quantification. Geese were 
vaccinated with 1.52x105 PFU/ml of irradiated Zika virus. Dose was based on pre-
irradiated viral titer. Immunizations consisted of 2 x 200 µl subcutaneous injections at 
the back of the neck in two different injection spots. Eggs were collected starting from 
week 6 after the first vaccination and stored at 4ºC until further use. 
 
Purification of IgY from Goose Egg Yolk 
Zika virus IgY was purified using polyethylene glycol. Briefly the egg yolk homogenate 
was thawed and centrifuged at 10,000 x g for 30 min 4 ºC. The supernatant was passed 
through a 0.2 µm sterile filter and concentrated using a 100 kDa (MilliporeSigma, 
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Burlington, MA) tangential flow unit. 12% (weight/volume) of 6,000 MW PEG was added 
to the concentrated supernatant that was then stirred for 30 min at room temperature. 
The PEG mixture was then centrifuged at 10,000 x g for 30 min 4 ºC. The supernatant 
was discarded and the pellet was resuspended to the original volume in 1x PBS. 12% 
6,000 MW PEG was then added to the resuspended pellet and mixed for 30 min at 
room temperature. The mixture was centrifuged at 10,000 x g for 30 min 4 ºC and the 
pellet was saved. The pellet was resuspended in the original volume of 1x PBS (pH 7.4) 
and concentrated to 50ml using 100 kDa cassette (MilliporeSigma) the final sample was 
then diluted with 450ml of 1x PBS. Samples were additionally dialyzed in 1x PBS to 
remove residual PEG. 
 
Antibody Detection 
The binding activity of flavivirus IgY was determined by ELISA as previously described 
(155). Briefly 100 µl of antigen was coated onto a 96 well micro plate and stored 
overnight at 4ºC. The following day the plate was washed 3x and then blocked with 
400µl of blocking buffer and incubated at room temperature for 30 min. The wells were 
washed three times and incubated with 100µl of IgY serially diluted 1:2 across the wells 
of the plate. The plate was incubated at 37ºC for 30 min. The plate was washed 3x and 
blocked at room temperature for 10 min. 100µl of biotinylated rabbit anti-goose IgY 
antibody in blocking buffer was added to the plate and incubated at 37ºC for 30 min. 
Following this, 100 µl of diluted strepavidin-HRP antibody in blocking buffer was added 
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to each well, and the plates were incubated at 37°C for 30 min. Finally, the plate was 
washed 3x and 100µl of o-phenylenediamine dihydrochloride color substrate was added 
to each well and developed at room temperature protected from light for 15 min. The 
reaction was stopped by adding 50µl of 1N H2SO4, and the absorbance was read in a 
BioTek plate reader at A490. Data are represented as endpoint titers.  
 
 
Plaque Assay  
Vero cells were seeded into 6 well plates at 2x105 cells/well and allowed to come to 
confluency. Viral stocks were thawed in a 37ºC water bath and diluted from 10-1 to 10-7 
in cDMEM. Triplicate wells were infected with 250µl of viral dilutions whereas cell 
controls were inoculated with media alone. Plates were placed at 37ºC, 5% CO2 for 1 
hour lightly shaking every 15 min. The viral inoculum was removed, and the wells were 
washed with 1x PBS. Next, 3ml of 1:1 of 2% methyl cellulose and cDMEM mixture was 
added to each well. Plates were incubated for 7 days (ZIKV) and 10 days (DENV). At 
the end of the incubation, the overlay was removed and the cells were fixed with 400 µl 
of 10% formalin for 30 min at room temperature Formalin was removed and crystal 
violet solution was added to each well for 10 min to stain the cell layer. The crystal violet 
was removed and the wells were washed 3-5x with 1x PBS until plaques were clearly 
visible.  
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Plaque Reduction Neutralization 
The plaque reduction neutralization assay (PRNT) is similar to the plaque assay noted 
above with the following exceptions. The virus is diluted to 40-60 PFUs that is then 
treated with IgY ranging in concentrations from 250 µg/ml to 3.125 µg/ml. Plaques are 
then counted and a 50% or greater reduction of plaques was consider a significant 
reduction (in accordance with WHO standards) (223). 
 
Antibody Dependent Enhancement  
The presence of ADE was assessed using the protocol in Diamond, et al. with minor 
modifications (224). We used a MOI of 2 for ZIKV and 10 for DENV, due to the 
difference in binding kinetics between ZIKV and DENV noted in Charles and 
Christofferson (225). THP-1 cells were seeded at 1.76 x 104 cells/well for DENV 
infection and 1.2 x 105 cells/well for ZIKV to accommodate for differences in titer of the 
viral stocks. Antibody treatment was done with 300 ng of mAb 4G2 (Anti-flavivirus group 
antigen antibody, Novus) 1 µg and 100 µg of anti-ZIKV IgY were incubated at 37ºC, 5% 
CO2 for 1 hour prior to infection. Cells were infected for 90 min at 37ºC, 5% CO2. After 
infection cells were centrifuged at 900 x g for 5 min and washed 3x. Cells were 
suspended in cDMEM. Identical concentrations of the treatment antibody were added to 
cells and incubated for four days at 37ºC, 5% CO2. Cells were centrifuged again and the 
supernatant was collected and viral titer was determined by plaque assay. 
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In vivo ZIKV-Specific IgY Protection  
The therapeutic potential of ZIKV-specific IgY was tested using conditions that 
cause 100% mortality in IFNAR-/- mice. 3 week old IFNRA-/- mice were challenged with a 
lethal dose of ZIKV PRVABC59 (1.0x104 PFUs) intravenously (i.v.) via the retro-orbital 
sinus. 24 and 48 hours after infection, mice were injected intraperitoneally with the 
indicated amounts of ZIKV-specific IgY or control naïve IgY in a volume of 100 μL, or 
100 μL of PBS as a negative control. Mice were observed twice daily for 14 days for 
signs of morbidity and mortality. 
 
Viral Load Quantification   
At the mortality end point or conclusion of the study tissue samples (brain, spleen, and 
liver) were processed for viral load. Briefly the tissues were collected in 1 mL of 
cDMEM, and homogenated using a bullet blender. The supernatant was then 
centrifuged at 4,500 x g for 10 min. The clarified supernatant was then diluted in 
cDMEM in order to allow for 20-50 plaques per well in a 6 well plate. The plaque assay 
protocol described above was then used to quantify viral load in the respective organs. 
Viral copy number in the respective organs was also quantified via RT-qPCR. Viral RNA 
was extracted from the clarified tissue supernatant with the Viral RNA mini kit (Qiagen, 
Hilden, Germany). We then utilized Zika virus Genesig Easy kit (Genesig, Plymouth 
Meeting, MA) to quantify the viral copy number of the infected organs.  
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Epitope Mapping 
Anti-ZIKV IgY epitopes were mapped using peptide arrays for E, prM, C, NS1, NS2a, 
NS3, and NS5 proteins. 11 amino acid overlapping 15mer peptides were covalently 
linked to a microarray slide (JPT Innovative Peptide Solutions, Mainz, Germany), 
according to the manufacturer’s protocol. Briefly an uncoated slide and the slide 
containing the microarray were gently laid upon one another separated by spacers. 50 
µg/ml of control naïve IgY or anti-ZIKV specific IgY was incubated on the slides 
overnight at 4ºC in a moist environment. Slides were then rinsed 5x with tris-buffered 
saline and Tween20 (T-TBS) for 4 min, then 5x for 4 min with 18.5-ohm water. The 
slides were then incubated with 1 µg/ml Cy5 goat anti-chicken IgY secondary antibody 
(Abcam, Cambridge, UK) for 45 min protected from light. Slides were washed 5x with T-
TBS and 5x ultra-pure water, and dried with dust-free, oil free, canned air. A Genepix 
4000 microarray reader was used to measure the fluorescent signal at a pixel size of 10 
µm. The signal intensity mean values were calculated for each of the 3 sub-arrays and 
corrected for background.  
 
Statistical Analysis 
Differences in PFU/ml and copy number between the antibody groups and controls as 
well as the comparison of organ weights between groups were analyzed using ANOVA 
with a Bonferroni post-test for multiple comparisons. Survival was measured using 
Kaplan Meir and Mantel-Cox tests. The Mann-Whitney test was used to compare the 
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difference in body weight percentages.  GraphPad Prism (Version 7.0a, GraphPad 
Sofware inc., CA) was used for statistical analysis with p values of < 0.05 considered 
significant.  
 
 
 
Results 
Antibody characterization  
The characterization of polyclonal anti-DENV2 has been demonstrated previously by 
our lab [14]. Following the polyethylene glycol purification of anti-ZIKV IgY, SDS-PAGE 
was used to verify the presence and purity of full length IgY and alternatively spliced 
IgY. We were able to detect both full length and alternatively spliced forms of anti-ZIKV 
IgY from the goose egg yolk homogenate (Fig. 3). An ELISA was then performed to 
detect the presence of ZIKV specific IgY and to determine the endpoint titer of our IgY 
preparation.  The mean endpoint titer of the samples tested was 1:160,000. 
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 Fig. 3: Anti-ZIKV IgY purification: Purity of anti-ZIKV IgY after the second PEG 
precipitation. Lane 1, supernatant from the PEG precipitation, lane 2, resuspended PEG 
pellet. Lanes 3 and 4, molecular weight concentration and diafiltration. Lane 5, 
molecular weight marker. Lane 6, control naïve IgY that was previously purified via 
mercapto-ethyl pyridine HyperCel Hydrophobic Charged Induced Chromatograph for 
comparison. 
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In vitro viral neutralization and enhancement of Zika-specific IgY 
Polyvalent anti-ZIKV IgY was purified from goose egg yolks that were tested for 
neutralization capacity. Concentrations ranging from 250 µg/mL to 3.125 µg/mL were 
utilized to determine the neutralization capacity of anti-ZIKV IgY. 40-50 PFUs of Zika 
virus PRVABC59 was treated with anti-ZIKV IgY and then inoculated onto Vero cells to 
determine the NT50. The concentration that yielded the NT50 was 25 µg/mL (Fig. 4a). To 
determine if anti-ZIKV IgY induces ADE the experimental positive control Pan-flavivirus 
IgG 4G2 antibody produced a productive viral replication cycle in THP-1 cells yielding a 
significantly higher viral load compared to the untreated viral infection. The ZIKV-
specific IgY did not enhance viral burden at any of the concentrations tested (Fig. 4b). 
Cross reactivity and potential enhancement of a secondary Dengue virus infection was 
also assessed as described above and no viral enhancement was demonstrated in a 
DENV-2 infection of THP-1 cells. 
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Fig. 4: Anti-ZIKV IgY neutralizes ZIKV in vitro without antibody-dependent 
enhancement. A.) Anti-ZIKV IgY neutralized ZIKV infection in vitro with a NT50 of 25 
µg/mL. B.) Purified anti-ZIKV IgY did not enhance infection in vitro when virus was 
treated with 1µg/mL of IgY, whereas control 4G2 flavivirus IgG resulted in a significant 
increase of infection. C.) Purified anti-ZIKV IgY did not enhance ZIKV infection in vitro at 
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100 µg/mL. D.) Purified anti-ZIKV IgY did not enhance DENV2 infection in vitro at 100 
µg/mL, where 4G2 flavivirus IgG significantly enhanced the viral load. ****p=<0.0001, 
ns=not significant. 
In vivo efficacy of ZIKV-specific IgY 
IFNAR-/- mice were challenged with a lethal dose of ZIKV PRVABC59 (1x104 PFUs) and 
the therapeutic potential of ZIKV-specific IgY was determined (Fig. 5). The results of 
four independent experiments using a lethal dose of 1x104 PFUs were combined. Mice 
receiving only PBS as a negative control succumbed to the infection by 6 days post 
infection. An initial dose of 500 µg of ZIKV-specific IgY (n=6) 24 hours post infection 
significantly extended the lifespan but did not allow for recovery from infection and all 
mice succumbed to infection by day 7. 500 µg of ZIKV-specific IgY(n=7) administered 
24 and 48 hours post infection lead to 85% therapeutic efficacy. This dose significantly 
reduced infectious viral load and genomic viral copies in the brain, liver, and spleen 
(Fig. 6). We achieved 100% therapeutic efficacy with 1 mg of ZIKV-specific IgY (n=6) 
administered 24 and 48 hours post infection. This regimen resulted in sterilizing 
immunity in all mice measured by infectious viral load and viral genomic copies (Fig. 6). 
Naïve IgY was used as a control, two doses of 500 µg and 1 mg did extend the mice’s 
lifespan but no subjects survived the challenge.  
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 Fig. 5: Therapeutic efficacy of anti-ZIKV IgY in vivo. 3 week old IFNAR-/- 
mice were administered a lethal dose of ZIKV i.v. in 100 µL total volume. At 24 and 48 
hour post infection mice were immunized i.p. with the indicated amount of antibody in a 
volume of 100µL. Control mice were treated with 100 uL of PBS. Panels A and C 
demonstrate the survival outcome of the treatments. B.) Weight was monitored daily 
until day 14 or until morbid. Weights are reported as percent of starting weight, p-values 
are denoted when comparing groups to viral control. **p<0.01, ***p<0.005, ****p<0.0001 
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Fig. 6: Viral load reduction upon treatment with anti-ZIKV IgY. The viral load 
reduction upon treatment with anti-ZIKV IgY: (A–C) The infectious viral load was 
quantified in the brain (A), spleen (B), and liver (C) via a plaque assay. (D–F) The viral 
genomic copy number was quantified in the brain (D), spleen (E), and liver (F) via RT-
qPCR. The viral load of the treated mice was compared to the viral control group. *p < 
0.05, **p < 0.01, ***p < 0.005, ****p < 0.0001, and $ is the comparison to the matching 
ZIKV-specific IgY group. 
 
 
 
 
 
 
 
 
 
ZIKV-IgY Epitope Mapping 
Epitope mapping was implemented to determine the specificity of the ZIKV specific IgY. 
A pan-flavivirus microarray displaying overlapping linear epitopes of envelope (E), 
membrane (M), peptide pr (PR) capsid protein (C), Non-structural proteins 1, 2, 3, and 5 
(NS1, NS2A, NS3, NS5) reactivity was compared to negative control peptides MFI 
average. Unbiased heat maps were generated in order to compare ZIKV-specific IgY to 
control naïve IgY (Fig. 7). A majority of epitopes recognized by ZIKV-specific IgY were 
centralized on the M and NS5 protein. ZIKV-specific IgY did recognize a known 
neutralizing epitope on the E protein and a novel highly conserved NS1 epitope. We 
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measured the potential cross reactivity of the polyclonal Zika specific IgY with other 
flaviviruses via microarray analysis. We found significant cross reactivity with Dengue 
virus, Yellow Fever virus, and West Nile virus (Fig. 8). The epitopes corresponding to 
the number on the microarray are displayed in Table 2. The potential for cross 
neutralization of these three viruses will be tested in the future. 
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Fig. 7: Epitope mapping of structural and non-structural genes. A.) A heat map of 
structural epitopes of Zika virus recognized by Zika specific IgY and naïve IgY. B.) A 
heat map of non-structural epitopes of Zika virus recognized by Zika specific IgY and 
naïve IgY. The strength of binding is indicated on a colorimetric scale with red being 
strong binding affinity and green being no binding.  
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Fig. 8: Epitope mapping of structural and non-structural genes. A.) A heat 
map of structural epitopes of DENV recognized by Zika specific IgY and naïve IgY. B.) 
A heat map of non-structural epitopes of DENV recognized by Zika specific IgY and 
Zika IgY Naive IgY
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naïve IgY. C.) A heat map of structural epitopes of WENV recognized by Zika specific 
IgY and naïve IgY. D.) A heat map of non-structural epitopes of WENV recognized by 
Zika specific IgY and naïve IgY. E.) A heat map of structural epitopes of YFV 
recognized by Zika specific IgY and naïve IgY. F.) A heat map of non-structural epitopes 
of YFV recognized by Zika specific IgY and naïve IgY The strength of binding is 
indicated on a colorimetric scale with red being strong binding affinity and green being 
no binding. 
Position	 Dengue	Structural	Proteins	 Dengue	Non-Structural	Proteins	
1	 LEHGSCVTTMAKNKP	 E	 GTTVVVDEHCGNRGP	 NS1	
2	 TAWDFGSLGGVFTSI	 E	 KAKIIGADVQNTTFI	 NS1	
3	 QGEPSLNEEQDKRFV	 E	 ASAIQKAHEEGICGI	 NS1	
4	 PLPWLPGADTQGSNW	 E	 FIIDGPNTPECPSAS	 NS1	
5	 TTESRCPTQGEPSLN	 E	 MEIRPLSEKEENMVK	 NS1	
6	 QKETLVTFKNPHAKK	 E	 GTTVVITENCGTRGP	 NS1	
7	 LTLDCEPRSGIDFNE	 E	 MEIRPLSEKEENMVK	 NS1	
8	 NIEAEPPFGESYIVI	 E	 LENLMWKQITPELNH	 NS1	
9	 MAAILAYTIGTTHFQ	 M	 EKYQLAVTIMAILCV	 NS2A	
10	 MAYMIGQTGIQRTVF	 M	 IAGVFFTFVLLLSGQ	 NS2A	
11	 VEKVETWALRHPGFT	 M	 NQILEENVEVEIWTK	 NS3	
12	 SVALVPHVGMGLETR	 M	 FRKRKLTIMDLHPGA	 NS3	
13	 LFLAHAIGTSITQKG	 M	 TDGPERVILAGPIPV	 NS3	
14	 IGQTGIQRTVFFVLM	 M	 PGSRDPFPQSNAPIM	 NS3	
15	 SSEGAWKHAQRIETW	 M	 DAFPQSNAPIQDEER	 NS3	
16	 VPHVGMGLETRTETW	 M	 TATPPGATDPFPQSN	 NS3	
17	 FKTEDGVNMCTLMAM	 Peptide_pr	 EDMLTVWNRVWIEDN	 NS5	
18	 IDCWCNLTSTWVMYG	 Peptide_pr	 GEGLHRLGYILEEID	 NS5	
19	 EPRMIVGKNERGKSL	 Peptide_pr	 DVFYLPPEKCDTLLC	 NS5	
20	 CNLTSTWVMYGTCTQ	 Peptide_pr	 LGEKWKSRLNALGKS	 NS5	
21	 CPLLVNTEPEDIDCW	 Peptide_pr	 YFHRRDLRLASNAIC	 NS5	
22	 FKTTEGINKCTLIAM	 Peptide_pr	 GDDCVVKPLDERFGT	 NS5	
23	 RWGSFKKNGAIKVLR	 C	 HGSYEVKATGSASSM	 NS5	
24	 AFITFLRVLSIPPTA	 C	 KKVTEVKGYTKGGPG	 NS5	
25	 RKEIGRMLNILNGRK	 C	 DVFFIPPEKCDTLLC	 NS5	
26	 PTAGILKRWGQLKKN	 C	 YILRDVSKKEGGAMY	 NS5	
27	 LIGFRKEIGRMLNIL	 C	 YFHRRDLRLASMAIC	 NS5	
28	 LAKRFSKGLLSGQGP	 C	 QVRSLIGNEEYTDYM	 NS5	
29	 MNQRKKVVRPPFNML	 C	 QEEQGWTSASEAVND	 NS5	
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30	 		 		 YILEEIDKKDGDLMY	 NS5	
31	 		 		 KPTEQVDTLLCDIGE	 NS5	
32	 		 		 DLENPHLPEKKITQW	 NS5	
33	 		 		 LVKLHSGKDVFFIPP	 NS5	
34	 		 		 CVVKPLDDRFASALT	 NS5	
35	 		 		 SVWNRVWIEENPWME	 NS5	
36	 		 		 SRKEFDLYKKSGITE	 NS5	
37	 		 		 DVSKKEGGAMYADDT	 NS5	
 
Table 3: Corresponding epitopes to the heat maps of structural and non-
structural proteins of DENV recognized by anti-ZIKV IgY and naïve IgY. 
 
Position	 West	Nile	Structural	Proteins	 West	Nile	Non-Structural	Proteins	
1	 VVFAILLLLVAPAYS	 E	 ECPTQNRAWNSLEVE	 NS1	
2	 IDVKMMNMEAANLAE	 E	 NTLLKENGVDLSVVV	 NS1	
3	 EFEEPHATKQSVIAL	 E	 TRTTTESGKLITDWC	 NS1	
4	 SLTVQTHGESTLANK	 M	 CDSKIIGTAVKNNMA	 NS1	
5	 QTHGESTLANKKGAW	 M	 IIPITLAGPRSNHNR	 NS1	
6	 ESTLANKKGAWMDST	 M	 TPQGLAKIIQKAHKE	 NS1	
7	 KVMMTVNATDVTDVI	 Peptide_pr	 VSRLEHQMWEAVKDE	 NS1	
8	 CEDTITYECPVLAAG	 Peptide_pr	 VVDGPETKECPTQNR	 NS1	
9	 ITYECPVLAAGNDPE	 Peptide_pr	 EIDFDYCPGTTVTIS	 NS1	
10	 DVITIPTAAGKNLCI	 Peptide_pr	 ASTGVFNPMILAAGL	 NS2A	
11	 ITYECPVLSAGNDPE	 Peptide_pr	 LLVVFLATQEVLRKR	 NS2A	
12	 CEDTITYECPVLAAG	 Peptide_pr	 KEKRSSAAKKKGACL	 NS2A	
13	 PEDIDCWCTKSSVYV	 Peptide_pr	 FLELLRTADLPVWLA	 NS3	
14	 CPVLAAGNDPEDIDC	 Peptide_pr	 PGAGKTRRILPQIIK	 NS3	
15	 KSRAVNMLKRGMPRV	 C	 NPSQVGDEYCYGGHT	 NS3	
16	 		 		 QRRGRIGRNPSQVGD	 NS3	
17	 		 		 WLAYKVAAAGISYHD	 NS3	
18	 		 		 SAIVQGERMEEPAPA	 NS3	
19	 		 		 GRTTWSIHAGGEWMT	 NS5	
20	 		 		 VVPCRGQDELIGRAR	 NS5	
21	 		 		 RTWNYHGSYDVKPTG	 NS5	
22	 		 		 KDIQEWKPSTGWYDW	 NS5	
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23	 		 		 AENIHVAINQVRSVI	 NS5	
24	 		 		 ENEWMEDKTPVERWS	 NS5	
25	 		 		 STGWYDWQQVPFCSN	 NS5	
26	 		 		 VSRASGNVVHSVNMT	 NS5	
27	 		 		 EEQNQWRSAREAVED	 NS5	
28	 		 		 KNSGGGVEGLGLQKL	 NS5	
29	 		 		 GKREDIWCGSLIGTR	 NS5	
30	 		 		 HRRLARAIIELTYRH	 NS5	
31	 		 		 IERLRREYSSTWHHD	 NS5	
32	 		 		 YGWNIVTMKSGVDVF	 NS5	
 
Table 4: Corresponding epitopes to the heat maps of structural and non-
structural proteins of WENV recognized by anti-ZIKV IgY and naïve IgY. 
 
 
 
 
 
Position	 Yellow	Fever	Structural	Proteins	
Yellow	Fever	Non-Structural	
Proteins	
1	 KGTTYGVCSKAFKFL	 E	 WCCRSCTMPPVSFHG	 NS1	
2	 KVIMGVVLIWVGINT	 E	 AAVNGKKSAHGSPTF	 NS1	
3	 FGGLSWITKVIMGVV	 E	 AINFSKRELKCGDGI	 NS1	
4	 TALTIAYLVGSNMTQ	 M	 NLVFSPGRKNGSFII	 NS1	
5	 ERWLVRNPFFAVTAL	 M	 WKLEGRWDGEEEVQL	 NS3	
6	 ERWLVRNPFFAATAL	 M	 GKKLVPSWASVKEDL	 NS3	
7	 VRNPFFAVTALTIAY	 M	 WQVAKAGLKTNDRKW	 NS3	
8	 LQKIERWLVRNPFFA	 M	 EPTRVVNWEVIIMDE	 NS3	
9	 VTLVRRNRWLLLNVT	 Peptide_pr	 VTRMAMTDTTPFGQQ	 NS5	
10	 YGKCDSAGRSRRSRR	 Peptide_pr	 WHYCGSYVTRTSGSA	 NS5	
11	 YGKCDSAGRSRRSRR	 Peptide_pr	 KVDTRAKDPPAGTRK	 NS5	
12	 CWCYGVENVRVAYGK	 Peptide_pr	 RTTWSIHGKGEWMTT	 NS5	
13	 REEPDDIDCWCYGVE	 Peptide_pr	 WRDVPYLTKRQDKLC	 NS5	
14	 VTLVRKNRWLLLNVT	 Peptide_pr	 VSPGNGWMIKETACL	 NS5	
15	 TLVRRNRWLLLNVTS	 Peptide_pr	 GGVEGIGLQYLGYVI	 NS5	
16	 FSVGTGNCTTNILEA	 Peptide_pr	 KGPLDRAAIEERVER	 NS5	
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17	 GLAVLRKVKRVVASL	 C	 CVVRPIDDRFGLALS	 NS5	
18	 QKTKQIGNRPGPSRG	 C	 QDKTMVKEWRDVPYL	 NS5	
19	 WKMLDPRQGLAVLRK	 C	 GKVDTGVAVSRGTAK	 NS5	
20	 WKMLDPRQGLAVLRK	 C	 GKAYMDVISRRDQRG	 NS5	
21	 FNILTGKKITAHLKR	 C	 		 		
 
Table 5: Corresponding epitopes to the heat maps of structural and non-
structural proteins of YFV recognized by anti-ZIKV IgY and naïve IgY. 
 
 
Discussion 
 
The results reported herein show that anti-ZIKV IgY purified from goose egg yolk has 
the ability to neutralize ZIKV infection in vitro and in vivo without inducing ADE. We 
observed therapeutic efficacy with 1 mg of anti-ZIKV IgY administered 24 and 48 hours 
post infection in a lethal IFNAR-/- mouse model. Our results indicated that naïve IgY was 
able to partially delay death in a lethally infected mouse but all mice immunized with 
naïve IgY succumbed to infection. This is in contrast to previous data from our lab 
demonstrating non-specific protection in a lethal DENV2 mouse infection model (156). 
This may be due to unique structural features of ZIKV, the mature virion is more 
thermally stable allowing for less dynamic rearrangement making the fusion loop on the 
envelope protein more difficult to access (226,227). As indicated in Figure 1 there is a 
full length and alternatively spliced form of IgY. All experiments performed here utilized 
both the full length and alternatively spliced forms of IgY in our purified product. In the 
future these distinct forms will be separated and the neutralization capacity of each will 
be assessed.  
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Epitope mapping was implemented to determine the specificity of the ZIKV 
specific IgY and identify potential broad neutralizing epitopes. A pan-flavivirus 
microarray displaying overlapping linear epitopes of envelope (E), membrane (M), 
peptide pr (PR) capsid protein (C), Non structural proteins 1, 2, 3, and 5 (NS1, NS2A, 
NS3, NS5) was compared to negative control peptides. The mean fluorescent intensity 
of the negative control peptides was used to remove fluorescent signal from non-
specific binding. Unbiased heat maps were generated in order to compare ZIKV-specific 
IgY to control naïve IgY (Figure 5). We found that the peptide LHGTVTVEVQYAGTD of 
the IgG III like domain of the E protein was strongly recognized which is critical for cell 
receptor binding as well as endosomal fusion. A NS1 epitope was a highly recognized 
peptide, ESEKNDTWRLKRAHL, that is conserved across multiple strains of ZIKV. This 
epitope has not been previously identified in other antibody screening studies. Future 
studies are planned to isolate these epitope specific IgY populations and determine their 
ability to neutralize ZIKV. We measured the potential cross reactivity of the polyclonal 
Zika specific IgY with other flaviviruses via microarray analysis. We found significant 
cross reactivity with Dengue virus, Yellow Fever virus, and West Nile virus (data not 
shown). The potential for cross neutralization will be tested in the future.  
Since the production of antivirals and vaccines may be difficult, alternative 
therapies must be explored for emerging pathogens such as ZIKV. Avian IgY and egg 
powder has been declared by the United States Code of Federal Regulation as 
generally recognized as safe (GRAS) (228). The therapeutic potential of polyclonal 
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avian antibodies has been demonstrated for a number of pathogens. Gastrointestinal 
infections such as enterotoxic Escherichia coli, Salmonellal spp, Rotavirus, and 
Helicobacter pylori have been successfully treated in mice and humans utilizing IgY 
(229). IgY has also been implemented in Sweden as an orphan drug for the prevention 
of Pseudomonas aeruginosa in cystic fibrosis patients (228). We recognize that 
translating anti-ZIKV IgY to a human therapy will encounter challenges. It has been 
previously demonstrated that pigs and mice will develop a humoral response to avian 
IgY, notably the subclass IgG (229-231). Unpublished data from our lab demonstrated 
weekly IgY injections begin to produce anti-IgY IgG in the third to fourth week of 
immunizations. Purified IgY is unknown to have the ability to induce an allergic reaction 
in humans. What has been demonstrated is that raw egg yolk, purified IgY, and 
alternatively spliced IgY did not induce an IgE response in mice. Egg allergies are 
important to consider when implementing IgY as a therapy in case residual egg yolk 
lipids still remain in the purified product. Future allergenicity studies will need to be 
conducted to definitively determine if purified IgY induces an allergic response or not. 
 At the present there are no FDA approved vaccines or therapies for ZIKV 
infection. Multiple platforms; live attenuated, nucleic acid, vector, and peptide based, 
have been employed to develop a safe efficacious vaccine for ZIKV (232-234). A major 
conundrum for the development of a ZIKV vaccine is the risk of inducing ADE by a 
subsequent DENV infection. Settler et al demonstrated that cross-reactive ZIKV 
antibodies have the ability to enhance DENV infection (219). The severity of developing 
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a therapy without properly assessing its ability to induce ADE was demonstrated by the 
deployment of the tetravalent dengue vaccine that resulted in increased hospitalization 
in younger and serum naïve individuals (235). This study emphasized the need to 
produce vaccine and therapies for flaviviruses that do not induce ADE such as the case 
of anti-ZIKV IgY demonstrated here. IgY is similar to aglycosylated IgG as IgY does not 
bind to FcγR. IgY is advantageous because it does not require any genetic modification 
or post production processing to prevent enhancement. 
 Teratogenic pathology induced by ZIKV when a mother is infected and the 
infection spreads to the fetus is a major concern in the recent outbreak. Due to the 
causal relationship between ZIKV and the development of microcephaly lead the WHO 
to declare ZIKV a public health emergence and to expedite therapies needed to combat 
ZIKV infection. Taking this statement into account future studies will examine the 
therapeutic efficacy of immunizing dams with anti-ZIKV IgY and determining the 
prevention of viremia of the fetus. 
 In summary, our studies comprehensively characterized the therapeutic potential 
of anti-ZIKV IgY and demonstrated that IgY does not induce ADE. Our results indicate 
that utilizing a polyethylene glycol extraction method obtained a highly pure IgY product. 
Our purified anti-ZIKV IgY was able to inhibit ZIKV infection in vitro and did not induce 
ADE at multiple concentrations. Anti-ZIKV IgY therapeutically administered to mice 
protected against lethal ZIKV challenge. Epitope mapping demonstrated the recognition 
of known neutralizing E epitopes as well as novel NS1 epitopes unique to avians. Thus, 
	 72	
our study has addressed an important aspect of ZIKV infection, i.e., a safe and effective 
immunotherapy that may be utilized in an epidemic outbreak of ZIKV.  
 
Chapter V 
Avian antibodies targeting dengue virus NS1 neutralize infection in 
vitro and confer protection against lethal dengue disease in a mouse 
model 
Abstract 
Dengue fever is caused by four dengue virus (DENV) serotypes (DENV1-4) and 
is a continually increasing in global public health burden. A foremost challenge in 
dengue vaccine and immunotherapy development is that cross reactive anti-DENV 
antibodies can induce increased disease severity, via antibody dependent enhancement 
(ADE). DENV nonstructural protein 1 (NS1) is an attractive immunotherapy target, as 
antibody responses against this protein should not induce ADE. In this study, we 
evaluated the ability of avian antibodies (IgY) targeting epitopes in NS1 to neutralize 
DENV infection in vitro and in vivo. We characterized two unique anti-NS1 IgY 
preparations which were capable of neutralizing DENV infection in vitro, similar to an 
oligoclonal anti-DENV IgY preparation. Additionally, using ELISA we characterized the 
binding specificity of these two anti-NS1 IgY isolates across all four dengue serotypes, 
and established that they do not induce ADE in an in vitro system.  We also 
demonstrated that anti-NS1 IgY isolates did not block binding of soluble NS1 to 
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endothelial cells to prevent the disruption of endothelial monolayers. Finally, we showed 
that prophylactic treatment of mice with anti-NS1 IgY conferred significant protection 
against lethal challenge with DENV2. Taken together, our findings highlight the potential 
of anti-NS1 IgY antibodies as a promising prophylactic approach to prevent lethal DENV 
infection. 
Introduction 
Dengue virus (DENV) is a mosquito-borne positive single strand mosquito-borne 
RNA virus which is widespread in tropical and subtropical climates, and a significant 
global public health burden. DENV causes approximately 390 million infections per 
year, with 96 million will resultig in clinical disease and 500,000 patients requiring 
hospitalization (236). The majority of dengue cases present as flu-like symptoms and 
joint pain, known as dengue fever (DF). However, a subset of individuals develop more 
severe forms of the disease, including dengue hemorrhagic fever (DHF) and dengue 
shock syndrome (DSS). Severe DENV infection is characterized by increased vascular 
leakage, which causes hypotension and circulatory collapse leading to shock and 
potentially death (237).  
 The DENV nonstructural protein 1 (NS1) is a 48-55 kDa protein which induces 
endothelial hyperpermeability in vitro and vascular leakage in vivo. NS1 is secreted from 
DENV-infected cells and high levels of circulating NS1 in patients with severe dengue 
disease has been observed (238). In mice, administration of NS1 and a sublethal dose 
of DENV resulted in the production of pro-inflammatory cytokines TNFα and IL-6, as 
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well as in lethal vascular leakage syndrome (239). Circulating NS1 is capable of binding 
to the surface of endothelial cells in capillary beds (240). Further, interactions between 
the endothelial glycocalyx layer (EGL) and NS1 result in the up regulation of sialidases 
Neu1-3, which leads to the cleavage of sialic acid on the surface of the endothelial cells. 
Binding of NS1 to the EGL also induces an increased expression of cathepsin L, which 
in turn, over expresses heperanase and results in the cleavage of heparan sulfate and 
heparan sulfate proteoglycans. Together, these processes result in EGL degradation 
and loss of barrier integrity (241). Anti-NS1 antibodies capable of recognizing NS1 on 
the surface of DENV-infected cells can trigger complement activation and complement 
dependent cellular lysis (240). However, NS1 bound to uninfected cells can induce 
similar mechanisms and result in increased vascular disruption (242,243). Intracellular 
expression of NS1 is critical in the formation of viral replication complexes in the 
endoplasmic reticulum (ER) and deletion of NS1 halts viral replication (244-246). 
Indeed, NS1 co-localizes with viral RNA, as well as other non-structural proteins, to help 
stabilize the viral replication complex within the ER lumen. It has also been 
demonstrated that NS1 co-localizes with the structural E and prM proteins, which 
indicates that NS1 is involved in trafficking of mature virions to the cell membrane for 
efficient viral budding (247). Therefore, given the role of NS1 in the pathogenesis of 
severe dengue disease, and its functions in immune evasion and viral replication, it is 
reasoned that NS1 blockade could result in an effective therapeutic.  
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 Due to the challenges of developing an effective and safe vaccination for DENV 
alternative antiviral therapies need to be explored. IgY is the avian homologue of 
mammalian IgG and shares characteristics with mammalian IgG and IgE. IgY is the 
predominant isotype in sera after the initial production of IgM and is the primary 
antibody produced upon a secondary response (110,111). IgY is found in two isoforms 
in the serum of water-fowl; full-length IgY, which contains two constant regions and an 
alternatively spliced IgY, which lacks these two constant regions (125). Due to the 
phylogenetic distance between avian and mammalian species, a much broader range of 
epitope recognition and higher binding affinities are achieved, which allows for novel 
epitopes to be recognized (126,129). IgY comprises 75% of all immunoglobulins in 
avian hosts with concentrations of 5 mg/ml in serum (129). IgY has been utilized to treat 
human pathogens such as H. pylori, S. mutans, S. sobrinus, P. gingivalis, Rotavirus, 
and P. aeruginosa in Cystic fibrosis patients (227-230). An attractive characteristic of 
IgY for flavivirus infection is that IgY does not interact with mammalian FcγR, which 
eliminates the risk of ADE. This is critical for developing immunotherapies for DENV 
infection. Another unique characteristic of IgY is that it does not interact with the 
mammalian complement system, thus preventing off-target effects of anti-NS1 
antibodies by triggering lysis of non-infected cells (131). We employed the neutralization 
capabilities of IgY to non-structural protein 1 of DENV2.  
We previously demonstrated that avian IgY is effective at neutralizing DENV2 
infection in vitro and in vivo without inducing antibody dependent enhancement (ADE) 
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(156). Epitope mapping of a polyclonal anti-DENV IgY preparation revealed the 
presence of antibodies specific against NS1 epitopes. We hypothesized that these 
antibodies could neutralize NS1-induced pathology and be protective in a mouse DENV 
challenge model. We found that 2 IgY antibody preparations, denoted NS1-1 and NS1-
8, were effective at neutralizing the virus in vitro. However, these avian antibodies did 
not prevent soluble NS1 from binding to endothelial cells or limit endothelial permeability 
in vitro. Finally, passive transfer of NS1-specific IgY antibodies into interferon-α/β 
receptor-deficient C57BL/6 (Ifnar-/-) mice conferred significant protection against DENV-
induced morbidity and mortality.  
 
 
 
Materials and Methods 
Ethics statement 
Experimental procedures involving the use of animals were conducted in compliance 
with the Animal Welfare Act and in adherence to the recommendations in the Guide for 
the Care and Use of Laboratory Animals of the National Institutes of Health.  All 
experiments were approved and performed according to the guidelines of the 
Institutional Animal Care and Use Committee of the University of California, Berkeley.  
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Epitope specific IgY isolation  
Peptides 15 amino acids in length were produced by JPT Innovative Peptide Solutions 
for NS1 of DENV2. Utilizing AminoLink Plus Immobilization Kit (Thermo Scientific) IgY 
was isolated for specific epitopes. The protein was coupled to the AminoLink column 
according to the manufacture’s instructions. Briefly, the AminoLink Plus resin was 
resuspended and washed twice with pH 10 Coupling Buffer. Two ml of a 1.5 mg/ml of 
peptide solution specific for the epitope of interest were added to the column and was 
rocked end over end overnight. The column was centrifuged and washed with 2ml of 
Quenching Buffer twice. Two ml of Quenching Buffer were added and column were 
rocked for 30 minutes. The Quenching Buffer was then removed and the column 
washed four times with 1X PBS. Two ml of 6.9 mg/ml of DENV2 oligoclonal IgY were 
added to the column with 200 µl of Binding Buffer. The column was rocked end over 
end for one hour. The sample was removed and 1 ml of Binding Buffer was added and 
eluted into the same tube as the sample. Column was washed three times with 1x PBS 
and antibodies were eluted with 2 ml of Elution Buffer three times. A Coomassie Plus 
Assay Kit (Thermo Scientific Waltham, MA) was used to quantify the protein after 
elution. The microplate procedure was followed according to manufacture’s instructions.  
 
Viruses and cell lines 
DENV-2 VR-1584 and Zika virus PRVABC59 were propagated in Vero cells [American 
Type Culture Collection (ATCC)]. Briefly, Vero cells at 80% confluency in 6 well plates 
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were infected at an MOI of 0.1 and allowed to adhere for one hour at 37ºC 5% CO2. The 
cells were washed with DMEM containing 10% fetal bovine serum (FBS) (Atlanta 
biologicals, Atlanta, GA), Penicillin/Streptomycin (Corning, Corning, NY), and 2.5mM 
HEPES, (cDMEM). Three ml of cDMEM were replaced in the wells and the plates were 
incubated at 37ºC 5% CO2 for 5 days. The cell supernatant was centrifuged at 4,000 x 
g for 5 minutes to remove cell debris. The clarified cell supernatant was diluted 1:2 in 
heat inactivated fetal bovine serum and frozen at -80ºC. DENV2 D220 was generated 
from the parental strain DENV2 PL046 (247). The virus was propagated in Aedes 
albopictus C6/36 cell line (ATCC) and titered by plaque assays using baby hamster 
kidney (BHK) cells. 
 
Mice 
Interferon-α/β receptor–deficient C57BL/6 (Ifnar−/−) mice were bred and housed in 
specific pathogen-free conditions at the University of California, Berkeley Animal 
Facility. Five- to 8-week-old male and female mice were used for all experimental 
procedures. 
 
Lactate dehydrogenase assay  
Vero cells were seeded into 6 well plates at 2x105 cells/well. DENV2 was treated with 
25 µg of anti-NS1 IgY, control naïve IgY, and oligoclonal DENV IgY, and incubated for 1 
hour at 37ºC 5% CO2. Cells were then infected with 250 µl (MOI 0.1) and incubated for 1 
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hour at 37ºC 5% CO2. Viral inoculum was removed and cells were refed with cDMEM 
and incubated for 5 days at 37ºC 5% CO2. Cell supernatants were removed and a 
Pierce LDH Cytotoxicity Assay Kit (Thermo Scientific, Rockford, IL) was utilized to 
determine cytotoxicity per the manufacture’s instructions.  
 
Plaque assay  
Vero cells were seeded into 6 well plates at 2x105 cells/well. The cells were incubated 
37ºC 5% CO2 and were allowed to come to confluency. Viral stocks were thawed in a 
37ºC water bath and diluted from 10-1 to 10-7 in cDMEM. Wells were infected with 250 µl 
of viral dilutions in triplicate also cell controls were inoculated with media alone. Plates 
were placed at 37ºC 5% CO2 for 1 hour lightly shaking every 15 minutes. Viral inoculum 
was removed and the wells were washed with 1X PBS. Next, 3ml of 1:1 of 2% methyl 
cellulose and cDMEM were added to each well and the plates were incubated for 10 
days (DENV) and 7 days (ZIKV). At the end of the incubation the overlay was removed 
and 400µl of 10% formalin were added to each well and incubated for 30 minutes at 
room temperature to fix the samples. Finally, the formalin was removed and crystal 
violet solution was added to each well for 10 minutes to stain the cell layer. The crystal 
violet was removed and the wells were washed 3-5 times with 1x PBS until plaques 
were clearly visible.  
 
Neutralization assays 
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Neutralization assays were used to evaluate the ability of anti-NS1 IgY antibodies to 
block DENV infection in vitro. In brief, IgY antibodies were diluted to a starting 
concentration of 0.1 mg/mL. Ten 4-fold dilutions were mixed with equivalent volumes of 
DENV2 D220 for 1 hour before infecting U937 DC-SIGN cells, a DENV-permissive 
human monocytic cell line (248). Two hours following infection, cells were washed, and 
then fixed and stained for DENV E protein using 4G2 mAb-Alexa 488 24 hours later. 
The percentage of infected cells was calculated using a Guava flow cytometer (EMD 
Millipore) by gating Alexa 488-positive cells. The antibody dilution that reduced DENV 
infection by 50% (50% neutralizing antibody titer [NT50]) was calculated using Prism 
software (GraphPad).  
 
Antibody dependent enhancement  
ADE was assessed by co-incubating virus (MOI of 1) and antibody solutions for 1 hour 
at 37ºC 5% CO2 then added to 2x105 K562 cells/well and incubated for 1 hour under 
same conditions. Cells were then washed with 100 µl of cDMEM and maintained for 2 
days at 37ºC 5% CO2. Cells were fixed with 10% formalin for 30 min at room 
temperature. Cells were subsequently washed with FACS buffer and with flow 
cytometry perm buffer (TONBO, San Diego, CA) and stained with 4G2 mAb-Alexa 488 
conjugated antibody (Anti-flavivirus group antigen antibody, Novus Centennial, CO). 
Once stained and washed, the cells were analyzed via FACS and the number of Alexa 
488 positive cells were calculated (225).  
	 81	
 
ELISA 
Binding of IgY antibodies to the 4 DENV NS1 serotypes (DENV1, Nauru/Western 
Pacific/1974; DENV2, Thailand/16681/84; DENV3, Sri Lanka D3/H/IMTSSA-SRI/ 
2000/1266); and DENV4, Dominica/814669/1981) was evaluated by ELISA. Briefly, 
MaxiSorp® ELISA plates (Thermo Scientific Nunc) were coated with 50 μl of NS1 (The 
Native Antigen Company) (0.5 μg/ml) and incubated overnight at room temperature. 
After blocking with 1% BSA in PBS (1% BSA-PBS), wells were incubated for 1 hour at 
room temperature with anti-NS1 IgY antibodies. Plates were then washed and 
incubated for 1 hour at room temperature with horse radish peroxidase-labeled goat 
anti-chicken IgY (abcam) at 0.5 μg/ml in 1% BSA-PBS. The assay was developed using 
an ABTS-HRP substrate kit (SeraCare), according to the manufacturer’s specifications. 
 
NS1 binding assay 
A recently developed NS1 binding assay were used to determine if anti-NS1 IgY 
antibodies could prevent binding of NS1 to FreeStyle 293F suspension cells (Thermo 
Fisher Scientific) [Puerta-Guardo et al. 2019 Cell Rep.]. Briefly, eight 3-fold IgY antibody 
dilutions were mixed in 96-well tissue culture plates with recombinant His-tagged 
DENV2 NS1 (10 ug/ml) and incubated for 30 min using gentle oscillation. A suspension 
of 5 x 104 293F cells was then added to each well and incubated for 45 min at 37°C, 
5%C02. Finally, an AlexaFluor 647-conjugated anti-His-tag antibody (mAb-A647) was 
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used to detect NS1 bound to the surface of 293F cells, and samples were analyzed by 
flow cytometry.  
 
Trans-endothelial electrical resistance (TEER) assay 
To determine if anti-NS1 igY antibodies could prevent NS1-induced endothelial 
hyperpermeability, human pulmonary microvascular endothelial cell (HPMEC) 
monolayers grown on a 24-well Transwell polycarbonate membrane system (Transwell 
permeable support, 0.4 mM, 6.5-mm insert; Corning Inc.) were incubated with NS1 (5 
µg/ml) and IgY antibodies. Endothelial permeability was evaluated by measuring TEER 
in ohms at sequential 2-h time points. Measurements were performed using an 
epithelial voltohmmeter with “chopstick” electrodes (World Precision Instruments). 
Transwell inserts containing untreated HPMEC cells were used as a negative control 
and inserts with medium alone were used for blank resistance measurements. Relative 
TEER was expressed as the ratio of resistance value as follows: [ohm(experimental 
condition) − ohm (medium alone)]/[ohm (nontreated endothelial cells) − ohm (medium 
alone)]. After 24 h of treatment, 50%of upper and lower chamber media was replaced 
by fresh endothelial cell medium. 
 
Dengue virus challenge experiments 
To evaluate the protective capacity of anti-NS1 IgY antibodies, mice were injected 
intraperitoneally (i.p.) with 5 µg of 4G2 mAb and 150 µg of IgY antibodies. Twenty-four 
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hours later, mice were infected with 3 x105 PFU of DENV2 D220 by intravenous (i.v.) tail 
vein injection. Mice were monitored for 10 days and scored for morbidity and mortality 
using a standardized 5-point system (249). 
 
 
Results 
Neutralization capacity of anti-DENV2 NS1 in vitro.  
Epitope anti-DENV2 NS1 IgY was column purified from the oligoclonal anti-DENV IgY 
stock. Each epitope was given a number ranging from 1-8 to denote a particular amino 
acid sequence. To assess potential candidates for further neutralization analysis each 
anti-DENV2 NS1 preparation was tested for inhibition of DENV-induced cellular 
cytotoxicity (Fig. 9A). Candidates that demonstrated a significant reduction in cellular 
cytotoxicity were then assayed for neutralization capacity via plaque reduction 
neutralization tests. Concentrations ranging from 100 µg/mL to 3.125 µg/mL were 
administered to determine the 50% neutralization titer (NT50).  In these experiments, the 
NT50 of NS1-1 estimated at was 3.125 µg/mL while NS1-8 was 6.25 µg/mL (Fig. 9B-C). 
In adition, using a flow cytometry-based neutralization assay the NT50 of NS1-1 and 
NS1-1 were 1.2 µg/mL and 1.6 µg/mL, respectively (Fig. 9D).  
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Fig. 9: Anti-DENV2 NS1 IgY neutralizes DENV2 in vitro. 
A.) Multiple unique NS1 epitope IgY preparations assayed for the reduction of 
cytotoxicity. B.) Purified anti-NS1-1 IgY PRNT NT50 3.125 µg/mL. C.) Purified anti-
NS1-8 IgY PRNT NT50 6.25 µg/mL. D.) Serial dilutions of IgY antibodies were tested 
for neutralization of DENV2 D220. Data were fitted with a four-parameter sigmoidal 
dose-response curve to estimate the 50% neutralizing antibody titer (NT50). Data are 
representative of 2 independent experiments. 
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Anti-DENV2 NS1 IgY binds NS1 from multiple DENV serotypes 
Each of the anti-DENV2 NS1 IgY preparations that demonstrated significant 
neutralization were assessed by ELISA for their ability to bind to NS1 from the 4 DENV 
serotypes. NS1-1 was capable of binding to the 4 DENV NS1 serotypes at higher 
concentrations, but showed a higher affinity for DENV2 NS1 and DENV 3 (Fig. 10A). A 
similar trend was observed for NS1-8 (Fig. 10B). Higher concentrations of naïve IgY 
bound non-specifically to serotypes DENV2 NS1, DENV3 NS1, and DENV4 (Fig. 10C). 
This data demonstrates a broad recognition of multiple serotypes of DENV NS1 by anti-
NS1 IgY antibodies with a preference DENV2 NS1, the serotype used to immunize 
geese for IgY production.  
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Fig. 10: Anti-NS1 binding to DENV NS1. NS1-1 (A.) NS1-8 (B) and naïve (C) IgY 
antibodies were serially diluted and binding to NS1 protein from each of the four 
serotypes was measured by ELISA.   
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Anti-DENV2 NS1 IgY does not induce ADE of DENV or ZIKV 
As NS1 is not a structural protein, anti-NS1 should not facilitate ADE of mature virions. 
To test this, we utilized the bone marrow lymphoblast cell line K562 which are not 
permissive to flaviviral infection except via the FcR, to determine if anti-NS1 Igy 
antibodies could mediate ADE. As measured via FACs. NS1-1 and NS1-8 did not 
enhance either DENV infection or ZIKV infection of K562 cells (Fig. 11A-B).  
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Fig. 11: Anti-NS1 IgY antibodies do not enhance in vitro DENV or ZIKV infection. 
DENV or ZIKV were incubated with serially diluted anti-NS1 IgY antibodies and used to 
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infect K562 cells. The 4G2 mAb, specific for the flavivirus envelope protein, was used 
as a positive control.  
 
Anti-DENV NS1 IgY antibodies do not inhibit NS1 cell binding or NS1-
induced endothelial permeability 
To address if our anti-DENV NS1 IgY antibodies can prevent NS1 cell binding, each of 
the anti-IgY preparations were incubated with soluble NS1 and then added to 293F 
cells. At the tested concentartions, NS1-1 and NS1-8 were unable to inhibit NS1 binding 
to 293F cells (Fig. 12A). Further, we used a TEER assay to evaluate the ability of anti-
NS1 IgY antibodies to prevent NS1-induced endothelial barrier dysfunction of HPMECs. 
In these experiments, NS1-1 and NS1-8 were unable to prevent the loss of electrical 
resistance due to increased endothelial permeability (Fig. 12B-E).  
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Fig. 12: Soluble NS1 binding and TEER assays: A.) NS1 binding to the surface of 
293F cells in the presence of anti-NS1 IgY antibodies was measured by flow cytometry. 
An anti-His-tag antibody (mAb-A647) was used to detect NS1 bound to the surface of 
293F cells. The mouse monoclonal antibody (mAb) 2B7, specific for NS1, was used as 
a positive control.  B.) HPMECs were grown on Transwell semi-permeable membranes 
(0.4 mm pore size), and DENV2 NS1 protein (5 µg/mL, 1.5 ug total protein) in 
combination with IgY antibodies or controls were added to the apical chamber. A TEER 
assay was used to assess the effect of IgY antibodies on NS1-induced endothelial 
permeability at indicated time-points over 48 h. Naïve IgY was unable to block soluble 
NS1 from inducing loss of electrical resistance in the endothelial monolayer. C.) 2B7 
was able to inhibit the decrease in electrical resistance of the endothelial monolayer 
caused by soluble NS1. D.) NS1-1 IgY was unable to block soluble NS1 from inducing 
loss of electrical resistance in the endothelial monolayer. E.) NS1-8 IgY was unable to 
block soluble NS1 from inducing loss of electrical resistance in the endothelial 
monolayer. 
 
In vivo efficacy of Anti-DENV NS1 IgY  
To determine if anti-NS1 IgY antibodies could protect against DENV-induced morbidity 
and mortality, Ifnar-/- mice were prophylactically treated with 150 µg of anti-DENV2 NS1 
IgY antibodies or naïve IgY. Twenty-four hours post treatment, mice were challenged 
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with 3 x 105 PFU of DENV2 D220 using ADE conditions and morbidity and mortality 
were monitored for 10 days. Notably, none of the mice treated with NS1-8 IgY showed 
signs of morbidity or succumbed due to DENV infection (Fig 13 A). However, survival 
among Ns1-1 IgY-treated mice was only 50%, while only 25% of the animals treated 
with naïve IgY or PBS did not succumb upon DENV challenge (Fig 13 B).  
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Fig. 13: Passive transfer of anti-NS1 IgY antibodies decreases DENV-induced 
morbidity and mortality in Ifnar-/- mice. IgY antibodies (150 µg) were passively 
transferred into Ifnar-/- mice and, 24 hours later, challenged i.v. with lethal antibody-
enhanced DENV2 D220 infection. (A) Signs of DENV-induced morbidity were recorded 
daily for 10 days. The proportion of each group of mice displaying the indicated signs is 
shown. (B) A Kaplan–Meier survival curve is shown. Animals treated with anti-NS1 IgY 
antibodies were significantly protected compared to Naïve IgY or PBS-treated controls. 
 
Discussion 
Several groups have created monoclonal antibodies to DENV NS1 protein. A 
majority of these antibodies target the wing domain, which enables the antibody to bind 
to the hexameric NS1 lipid complex structure preventing the pathology induced by 
soluble NS1 binding to endothelial cells (250-254). Due to the unique maturation steps 
of the colonial expansion of avian antibodies, we were able to generate two anti-NS1 
IgY molecules that target novel epitopes on NS1. The anti-NS1 IgY preparations 
demonstrated in vitro neutralization capacity similar to that of the oliogoclonal anti-
DENV IgY our lab has previously tested. To our knowledge this is the first anti-NS1 
antibody able to inhibit infection in vitro. We went on to further characterize the binding 
affinity to multiple serotypes of DENV NS1 and saw that at high concentrations anti-NS1 
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IgY is able to bind multiple serotypes of DENV NS1, but at lower concentrations a 
preference for DENV2 was seen in both anti-NS1-1 and NS1-8 IgY. This can be 
attributed to the serotype of DENV that was originally used to make the oligoclonal anti-
DENV IgY, which was used to isolate the epitope specific NS1 IgY was DENV2.  We 
then tested the ability of anti-NS1 IgY to block soluble NS1 from binding endothelial 
cells, which is the typical neutralization mechanism of anti-NS1 antibodies. We 
determined that anti-NS1-1 and NS1-8 IgY were unable to block soluble NS1 from 
binding to endothelial cells or inhibit vascular permeability measured by relative TEER. 
This may be due to the fact that the epitopes that NS1-1 and NS1-8 target are on the 
inside of the hexamer lipid complex making them inaccessible in that form. A secondary 
explanation could be that the epitopes recognized by NS1-1 and NS1-8 are not required 
for NS1-endothelial cell interactions. We next assessed the ability of anti-NS1-1 and 
NS1-8 IgY to protect mice from lethal DENV infection. Intriguingly, NS1-8 conferred 
stronger protection against DENV-induced morbidity and mortality than NS1-1.  
 Due to the challenges of developing immunotherapeutics for flaviviral infections 
alternative therapies that do not induce ADE are critical in combating increasingly 
prevalent disease burden. Avian IgY and egg powder have already been utilized to treat 
veterinary and human infections and have been recognized as safe agent by the United 
States Code of Federal Regulation (228). To translate anti-NS1 IgY to a human therapy 
there are still challenges associated with IgY treatment that must be overcome. One 
challenge that has been previously shown is that porcine and mice develop a humoral 
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response to avian IgY, notably subclass IgG (230,231). Unpublished data from our lab 
demonstrates that weekly immunizations with IgY in a mouse model will induce an anti-
IgY humoral response on the third or fourth weekly of vaccination. It is unknown if the 
hosts humoral immune system recognizes IgY, which is bound to the target antigen if 
the target antigen is still cleared by traditional antibody mechanisms. This would be 
especially important for flaviviral treatment to ensure that the high affinity IgY remains 
bound to the virus and the IgG molecule recognizing IgY would act as a trap antibody 
and utilize traditional clearance mechanisms. Being that IgY is isolated directly from the 
egg possible allergic reactions are a concern. It has not been demonstrated that purified 
IgY can induce allergic reaction in humans. What has been demonstrated is that purified 
IgY does not induce an IgE response in piglets (231). Future studies will need to be 
conducted to determine any risk of harmful allergic reaction due to purified IgY.  
 At the moment the only licensed vaccine for Dengue infection is Dengvaxia® 
Sanofi Pasteur (255). Due to apparent short comings in naïve patients which resulted in 
an increased risk of developing severe symptoms the vaccine was disbanded and the 
age range and serostatus criteria of patients receiving the vaccine were altered (256). 
The complications associated with Dengvaxia® has lead researchers to explore other 
targets for vaccine candidacy one of which is including NS1 in chimeric vaccine 
strategies. This will allow for a safer vaccine profile because of the decreased risk of 
ADE it will also directly target the pathogenic effects of the soluble NS1 protein that 
contributes to severe pathology. Two live attenuated vaccines from NIH and Takeda 
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included NS1 in their vaccine platforms (257). Human trials demonstrated that CD4+ 
and CD8+ T cells were induced by the vaccine NS1 protein, which solidifies the potency 
and immunogenicity of including it in additional vaccines in the future (258,259).   
In summary, our studies comprehensively characterized the protective capacity 
of anti-DENV NS1 IgY and demonstrated that anti-DENV NS1 IgY does not induce 
ADE. Our purified anti-DENV NS1 IgY preparations were able to inhibit DENV infection 
in vitro and did not induce ADE at multiple concentrations. Anti-DENV NS1 IgY 
antibodies were able to bind NS1 proteins from multiple serotypes, although they did not 
prevent soluble NS1 from binding endothelial cells nor did they inhibit NS1-induced 
hyperpermeability of endothelial cells. However, anti-DENV NS1 IgY prophylactically 
administered to mice protected against lethal DENV challenge. Taken together, our data 
indicate that the avian IgY platform has a promising prophylactic applications against 
DENV infection, which warrants further investigation. 
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Chapter VI 
Discussion 
The development of safe and effective anti-viral therapies is the corner stone and 
highest priority to combating emerging viral pathogens around the world. Vector 
competency studies should also be highly regard to know the extent in which the 
pathogen could spread and what areas should be considered for the implementation of 
vaccines or therapies. Our study on the vector competency of Aedes vexans was the 
first demonstration of a moderate climate mosquito able to be infected with and have 
the ability to transmit ZIKV. The relevance of this study impacted not only the addition of 
the mosquito species to the list of possible vectors, but it greatly expanded the 
geographical area in which this virus may potentially spread. Up until that study the 
known vectors were the traditional tropical mosquito vectors Aedes aegypti and 
albopictus both are traditional vectors of DENV as well. These two species of mosquito 
are confined to tropical regions and are slowly spreading to moderate climates because 
of changes in regional temperatures. The addition of Aedes vexans however to the 
competent vector list instantly makes the entire moderate climate a possible location for 
the spread of ZIKV. Aedes vexans is a flood water mosquito, and also one of the most 
common pest mosquitoes across most of the central United States and much of Europe. 
This is an excellent example of how complete vector competency profiles are necessary 
to determine the extent in which a pathogen can spread. The safety and efficacy of 
antibody therapy for flaviviral infections is of paramount concern. This can be extended 
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to not only the development of therapeutic monoclonal antibody therapies, but also the 
antibody responses elicited by a vaccine candidate. A recent cohort study in Nicaragua 
determined that after primary exposure to a flavivirus there is a specific antibody titer 
range in which the patient is more susceptible to ADE. This was demonstrated with not 
only different serotypes of DENV but also with ZIKV. A secondary example of this is in 
the recently recalled DENV vaccine Dengivax. This vaccine was developed by the 
Institute of Pasteur and showed strong efficacy against DENV serotypes 1, 3, and 4 and 
moderate protection against serotype 2. This was a high achievement due to traditional 
antigenic bias of previous vaccines that protected strongly against one serotype and 
moderate to weakly against the others. Once implemented into a high risk population 
however a critical characteristic had been over looked. In patients that were 
serologically naïve for DENV infection the vaccine actually increased their chance of 
developing sever dengue fever on secondary naturally acquired infection. It is 
hypothesized that the vaccine acted as the primary infection for these patients and 
because the circulating viruses were not genomically identical to the vaccine strain the 
primary antibody response held high titers of low affinity antibodies (256). Our lab’s 
reports on the safety profile and advantages of anti-flavivirus IgY demonstrates that 
alternative immunotherapeutics are not only effective, but preferable to the traditional 
human or mouse derived antibodies because they eliminate problems such as ADE. To 
expand upon the studies detailed herein our lab plans to explore the cross neutralization 
capabilities of different IgY preparations between flaviviruses. Preliminary studies 
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demonstrating that there is little in vitro efficacy of the oligoclonal anti-ZIKV or anti-
DENV2 IgY to cross reactive with the opposite virus (Fig. 14). This suggests a closer 
look at the epitope mapping is needed to determine optimal cross neutralizing 
antibodies to enrich future IgY preparations to enable the production of a “anti-flavivirus” 
IgY stock.  
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Fig. 14: Cytotoxicity of Vero cells treated with anti-DENV2 IgY infected with 
ZIKV. A.) Cytotoxicity five days’ post infection of cells infected with ZIKV and ZIKV 
pretreated with anti-DENV2 IgY. B.) Cytotoxicity seven days’ post infection of cells 
infected with ZIKV and ZIKV pretreated with anti-DENV2 IgY. 
A.) 
B.) 
	 102	
 
 
 
Another future direction of our lab is to isolate epitope specific IgY preparations from the 
polyclonal anti-ZIKV IgY stock to determine novel neutralization epitopes. Due to our 
prior success with anti-NS1 IgY with DENV, four stocks of anti-NS1 Zika IgY and a 
highly conserved NS5 epitope were isolated and PRNT was done to determine the 
extent of in vitro efficacy (Fig 15). Unlike the anti-NS1 for DENV the epitopes chosen did 
not exhibit any in vitro neutralization capabilities. What is yet to be determined is if there 
is efficacy of these epitopes in vivo, which is traditionally where you would see efficacy 
of an anti-NS1 antibody. To further expand upon the anti-ZIKV IgY project it is yet to be 
determined if IgY can cross the placental barrier to a developing fetus. This as well as 
functionality of the transferred IgY would need to be determined. Once that is done the 
protective efficacy of anti-ZIKV IgY to protect against trans-placental infection could be 
conducted.  
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Fig. 15: Anti-NS1 Zika IgY and anti-NS5 Zika IgY does not neutralize ZIKV infection in 
vitro at 100 µg/ml.  
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To continue our collaboration with the Biology department our lab plans to assist in 
studies determining if microfilariae infection of the midgut of mosquitoes can increase 
the dissemination rate of flaviviral infections. Previous work by Dr. Vaughan 
demonstrated that alphaviruses were able to attach to the microfilariae while they exit 
the midgut essentially utilizing them as a conductor to evade the midgut barrier. It was 
previously thought that the virus escaped as a result of the hole in the lining of the 
midgut tissue caused by the microfilariae exiting. After multiple years of working on 
avian antibodies there are areas of research in which I think the lab should pursue. The 
first is the production of dual specific antibodies. This has already been demonstrated 
and discussed previously with rotavirus and norovirus (50). This technique could easily 
be expanded to the two flaviviruses currently being studied in our lab. It would be my 
recommendation to target known highly neutralizing epitopes on the envelope of the 
viruses and construct a fusion protein for immunizations. It is known that the three 
dimensional orientation of this epitopes can greatly impact the potency of the antibodies 
being produced. As a result, extensive protein analysis would have to been done in 
order to determine the conformation of the two epitopes once fused together. Not only 
could this greatly expand the industrial potential of flaviviral IgY, but it could also 
increase the potency of it’s immunotherapeutic value. Upon the same lines IgY 
hybridoma production is necessary for IgY to take the next step into acceptance in 
modern medicine. The continual production of a specific antigen immunoglobulin would 
greatly cut down on quality control and quality assurance costs and variability. This is 
not to say that the polyclonal IgY stocks do not have their place as therapeutics, but in 
an age that is moving closer to personalized medicine specificity and targeting of 
therapies is becoming increasingly valued. A final thought for the future direction of the 
lab is to continue the virology aspect, but to start the process of manipulating viral 
vectors for the production of antigen specific immunization. This will allow for the 
production of site specific interactions while still allowing for the avian system to 
recognize novel epitopes within the target protein being expressed. This could decrease 
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the screening time necessary to the discovery of novel epitopes as well as increasing 
the antigenicity within the avian host itself resulting in the increased production of 
antigen specific IgY titers. Recently a paper described utilizing a viral vector for not only 
antigenic epitope display it also encoded the genomic sequence to express a highly 
potent monoclonal antibody (260). A technique similar to this could be employed to 
immunize subjects against DENV NS1 which has been shown to be protective in mice 
(250-254), but also to produce anti-DENV2 IgY specific for the envelope protein. This 
would allow for the targeting of the traditional structural epitopes that have been shown 
to have high potency, but can induce ADE and natural host immunity to a viral antigen 
with protective properties devoid of ADE thus targeting the invading virus structurally 
and the secondary proteins used to induce pathology.   
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